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The aim of this dissertation is to repurpose two drugs 1) antifungal ciclopirox 
olamine (CPX) and 2) lysophospholipid sphingosine-1-phosphate (S1P) as a 
proangiogenic combination to promote diabetic skin wound contraction. 
Contraction involves the pulling of perilesional skin into the wound to reduce 
wound area. Here, forces driving contraction arises from the compaction of 
collagen fibers in the granulation tissue and this process requires a robust 
angiogenesis. In diabetics, both angiogenesis and wound contraction are 
diminished leading to impaired wound healing. To emulate this pathology and 
to address it pharmacologically, I developed a wound healing model in the 
diabetic Zucker fatty rat and topically treated it with CPX+S1P. Using in vitro 
approaches, I demonstrated that CPX+S1P upregulates a crucial driver of 
angiogenesis, hypoxia-inducible factor-1, in endothelial cells. Injection of 
CPX+S1P into subcutaneously implanted sponges in experimental rats showed, 
in an additive manner, a fivefold increase in endothelial infiltration and lectin-
perfused vessel length. Further, I developed a splinted diabetic rodent model to 
achieve low wound contraction rates that are characteristic for the healing mode 
of diabetic ulcers in humans. I discovered specific dorsal sites that allowed for 
incremental full thickness excisional wound depths from 1 mm (superficial) to 3 
mm (deep). This enabled me to reduce wound contraction from 51% in 
superficial wounds to 8% in deep wounds. While the effects of topical gel 
treatment of CPX+S1P were masked by the rodent-characteristic dominant 
contraction in superficial wounds, they became clearly evident in deep diabetic 
wounds. Here, a fivefold increase of functional large vessels resulted in 
ix 
 
accelerated granulation tissue formulation, accompanied by a 40% increase of 
compacted thick collagen fibres. This was associated with substantially reduced 
matrix metalloproteinase-3 and -13 expression. These findings translated into a 
fivefold increase in granulation-driven contraction, promoting diabetic wound 
closure. With CPX and S1P analogues already in clinical use, their combination 
presents an attractive proangiogenic treatment to be repurposed to promote 
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1.1 Goal: Accelerate diabetic wound closure 
 
Diabetes (Diabetes mellitus) is a metabolic syndrome characterized by a chronic 
elevation of blood glucose levels, rising beyond 130 mg/dL after 8 hours of 
fasting [1]. This metabolic syndrome arises from defects in insulin action, insulin 
secretion from pancreatic beta cells or both [2]. Since the early 1960s, diabetes 
has been well established to impair skin wound closure [3-5]. Prolonged 
impairment in wound closure (i.e., ulcer) is an avenue for infection leading to 
cellulitis, myositis, abscesses, necrotizing fasciitis, septic arthritis, tendinitis, and 
osteomyelitis [8]. Consequently, foot ulcers are a major risk factor for diabetes-
related amputations [9,10],with a lower leg lost to diabetes globally every 20 
seconds [11]. As the prevalence of diabetes is set to increase globally from 8.3% 
of the population in 2013 to 9.9% by 2030, diabetes-related amputations are 
predicted to rise [11]. Unfortunately, a simple normalization of blood glucose 
levels alone is insufficient to reverse the long-term side effects of diabetes 
including impaired skin wound closure [6,7]. Thus the goal of this study is to 
develop an adjuvant therapy to accelerate diabetic wound closure.  
 
1.2 Focus: Increase wound contraction 
 
Wound closure depends on two mechanisms: (1) re-epithelialization and (2) 
contraction [12]. Re-epithelialization refers to the migration of epidermal cells to 
cover the denuded epithelial area [28]. Contraction reduces the area needed for 
re-epithelialization by pulling perilesional skin into the wound (§2.1). While being 
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aware that both mechanisms are impaired in chronic wounds [13,28], I have 
chosen to focus on promoting contraction under diabetes.  
 
The contribution of contraction to wound closure depends on regional human 
anatomy. It ranges from 21% on the forearm [14,15] to 90% in regions with less 
tight fastening to underlying structures such as the trunk or perineum  [16]. In 
humans, wound contraction is principally driven by the compaction of collagen 
fibers in the granulation tissue [17]. This process crucially depends on a robust 
formation of new blood vessels (angiogenesis) in the granulation tissue. 
Angiogenesis accounts for up to 60% of the granulation tissue mass [18], with 
vessel densities exceeding that of uninjured tissues by more than 3-fold [19]. 
This initially overshooting angiogenesis ensures cellular traffic, delivery of 
nutrients and oxygen required for collagen synthesis and maturation, and also 
aerobic respiration to generate ATP to drive the contraction and compaction of 
collagen fibers by fibroblasts.  
 
Diabetic wounds typically exhibit a low angiogenic response [2]. This in part 
explains their impaired granulation tissue formation and consequently impaired 
wound contraction [13,20]. Thus to accelerate granulation formation and 







1.3 Proangiogenic Drug Strategy: CPX+S1P  
 
To develop a proangiogenic strategy (Figure 1.1), I first identified major 
inhibitors of angiogenesis in diabetic wounds (§2.4). These are:  
(i) high reactive oxygen species (ROS) levels; 
(ii) high advanced glycation end products (AGEs) levels;  
(iii) low hypoxia-inducible factor 1 (HIF-1) activity;  
(iv) high matrix metalloproteinase (MMP) levels; and  
(v) low sphingosine-1-phosphate (S1P) levels.  
 
To overcome these angiogenic inhibitiors, a review of the literature suggests a 
combination of divalent metal chelators and S1P supplementation might hold 
promise (§2.4). In addition, a laboratory colleague Lim Sei Hien, recently 
discovered that ciclopirox olamine (CPX), a divalent metal chelator, in 
combination with S1P (CPX+S1P) synergistically increases endothelial 
sprouting in vitro (§2.6.2) [21]. Both drugs are also clinically available. CPX is a 
FDA-approved topical anti-fungal agent while S1P’s analogue is FDA-approved 
as an oral treatment for multiple sclerosis. Here drug repurposing and drug 
synergy is an attractive translational strategy for diabetic wound treatment. 
 
1.4 Formulating hypotheses 
To date, it remains unknown if CPX+S1P is able to: 
(i)  hyperinduce the angiogenic master regulator, hypoxia inducible factor (HIF-
1) (§2.3.4);  
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(ii) potentiate angiogenesis in vivo; or 
(iii) increase diabetic wound contraction.  
 
Accordingly, I formulated three hypotheses (§2.7); namely: 
(1) CPX+S1P potentiates HIF-1 activity in vitro; 
(2) CPX+S1P potentiates angiogenesis in vivo; and 
(3) CPX+S1P increases diabetic wound contraction. 
 
1.4.1 Methodology to test Hypothesis 1 
 
To assess if CPX+S1P potentiates HIF-1 activity in vitro (§3.1), I assessed the 
protein expression of (i) HIF-1 upstream regulators (HIF-1α, phosphorylated 
p42/44 MAPK) and (ii) HIF-1 downstream targets (VEGF, c-MET, eNOS) in 
monolayer culture of human endothelial cells. Their protein expression were 
compared among mono and combinatory treatments of CPX and S1P. 
 
1.4.2 Methodology to test Hypothesis 2 
 
To assess if CPX+S1P potentiates angiogenesis in vivo (§3.2), I adopted a well-
established subcutaneous rodent sponge implantation model and intradermally 
injected the drugs into the sponge over 2 weeks. Thereafter I assessed (i) 
endothelial infiltration and (ii) functional vessel length in the sponge. These 





1.4.3 Methodology to test Hypothesis 3  
 
To assess if CPX+S1P increases diabetic wound contraction, I develop a full-
thickness skin excision diabetic rodent model that exhibits low skin wound 
contraction (§3.3, Figure 1.1). Rodents unlike humans have an innate ability for 
extensive wound contraction due to the presence of a subcutaneous panniculus 
carnosus muscle and loose attachment of the dermis, making the skin extremely 
mobile.  This limits the options to assess pharmacological treatments to improve 
granulation-driven wound contraction as in human skin. To develop a low 
contraction wound model, I exploited the presence of a dorsal fat pad in the 
Zucker diabetic fatty rat which allows for wound depth increment from ~1 mm 
(superficial wound) to ~3 mm (deep wound). This approach was combined with 
two existing humanized contraction techniques i.e., wound edge splinting and 
excision of panniculus carnosus.  CPX+S1P was then topically delivered to 
superficial and deep wounds in a carboxymethylcellulose gel every alternate 
day over a month. Thereafter I assessed the following parameters against the 
placebo gel treatment: 
 
(i) wound closure and contraction; 
(ii) collagen deposition and collagen fiber thickness;   
(iii) MMP-3 and MMP-13 protein expression; 
(iv) functional vessel density and size; and 





1.5 Research Strategy Flowchart 
 





















2.1 Wound closure mechanisms 
 
2.1.1 Basic structure of skin 
 
Skin, in the strictest sense, refers to the layer of epidermis and dermis [22], but 
at times, the layer of subcutaneous fat directly attached to the dermis has also 
been considered to be a component of skin [22] (Figure 2.1). The outermost 
layer of skin is the epidermis. It is thin and avascular, being made up of four 
main layers of keratin producing cells called keratinocytes [23]. The epidermis 
is separated from the underlying dermis by the dermal epidermal junction also 
known as the basement membrane. At this junction, the downward rete ridges 
from the epidermis interlocks with the upward ridges from the dermis anchoring 
the epidermis to the dermis, preventing their sliding motion [23].  
 
The thickest layer of the skin is the dermis. Its thickness ranges from 2 mm to 4 
mm in humans, being anatomically site dependent [23]. Unlike the epidermis, 
the dermis comprises mainly of extracellular matrix (ECM) and is sparsely 
populated by cells. The primary cell type in the dermis is the fibroblast, which 
synthesises and remodels the major dermal ECM components: collagen types 
I and III (which occur in a proportion of 4:1) and elastin [24]. The dermis is further 
subdivided into two layers, the papillary dermis and the reticular dermis. The 
papillary dermis is thin and highly vascular, having finger-like projections into 
the epidermis [23]. The reticular dermis is thick, comprising of 80% of the dermis. 
Here sweat glands, nerves, hair follicles and blood vessels are surrounded by 
collagen bundles. Collagen is the major structural protein in skin, forming 75% 
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of the skin’s total dry weight. It gives the skin its tensile strength and anchors 
the skin to the subcutaneous tissue beneath [23].  
 
Figure 2.1 The basic structure of skin. (Figure adapted from Baranoski S. 
(2010) [23]. Copyright © 2010 F.A. Davis. Note: Names of epidermal cell types 




2.1.2 Full-thickness wound closure mechanisms 
 
Full-thickness wounds, such as diabetic foot ulcers [25], involve the destruction 
of both the epidermis and the dermis layers. At times, full-thickness wounds 
extend to the destruction of underlying subcutaneous fat and connective tissue 
[12]. This is in contrast to a partial-thickness wound, wherein the tissue 
destruction extends into but not through the dermis. Full-thickness wound 
closure can be macroscopically identified by the disappearance of light-
reflecting new stroma that fills the wound bed (i.e., granulation tissue), and the 
replacement of a non-reflecting fully epithelialized surface (Figure 2.2) [15]. This 
process occurs through through two mechanisms: (i) re-epithelialization and 
(ii) contraction [15] (Figure 2.2).  
 
As this dissertation focuses on developing an adjuvant therapy that accelerates 
contraction in diabetic full-thickness skin wounds, I will briefly introduce re-
epithelialization and then delve into the development of wound contraction.  
 
Re-epithelialization involves a lateral migration of epithelial cells, mainly 
keratinocytes, to resurface the wound. In a non-chronic wound, this process  
usually begins within 24 hours after injury and can be identified by the thickening 
of epidermis immediately adjacent to the wound edge [24]. Here keratinocytes 
at the wound edge lose their firm attachment to the underlying dermis, and begin 
to migrate laterally across the wound while fixed keratinocytes near the wound 
edge proliferate rapidly and appear to migrate by moving over one another in a 
leapfrog fashion until the defect is bridged [26,27]. For a detailed review on 
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reepithelialisation mechanism, I refer the reader to a comprehensive review by 
Pastar et al. (2014) [28].  
 
Figure 2.2 Full-thickness skin wound closure mechanisms. Cross-section 
schematics (top) and macroscopic plan view (bottom) of wound closure. Blue 
line in macroscopic image denotes the re-epithelialized front and the green line 
denotes the contraction front. 
 
 
Contraction, on the other hand, refers to the pulling of perilesional skin towards 
the centre of the wound (Figure 2.2) [15]. In humans, contraction develops as 
collagen fibers in the granulation tissue is compacted generating a force that 
pulls the perilesional skin into the wound [17]. Wound contraction can be 
distinctly observed approximately 4 days post-injury and is usually complete by 
12-15 days after wounding [29-31]. It contributes to ~21% to 37% of wound 
closure area in the adult human forearm [14,15,32], increasing to ~90%  in the 
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trunk and perineum regions where skin is not tightly bound down to underlying 
structures [16]. Contraction is undesirable when it results in scar “contracture” 
which pulls deeper tissues, not only skin, toward the injury site, deforming facial 
features and limiting the excursion of joints. Nonetheless, contraction plays a 
crucial role in full-thickness skin wounds wherein a large amount of tissue is 
destroyed, leaving a gap which cannot be approximated [12]. Contraction also 
aids in reducing the area for re-epithelization [33]. 
 
2.2 Development of wound contraction  
 
Wound contraction is widely accepted to occur during granulation tissue 
development, requiring [34,35]:  
(i) fibroblast infiltration and proliferation,  
(ii) collagen synthesis and deposition,  
(iii) myofibroblast contractile forces, and  
(iv) fibroblast tractional forces.  
 
Importantly, these events are intimately supported by a robust development of 
blood vessels (angiogenesis) in the granulation tissue.  
 
2.2.1 Angiogenesis in granulation tissue 
 
The granulation tissue begins to form approximately 3 days post-injury [36]. It 
consists of cellular elements including fibroblasts, inflammatory cells, along with 
abundant new capillaries embedded in a loose extracellular matrix of mainly 
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fibrous collagen (type I, III and IV) enriched in proteoglycans, 
glycosaminoglycans, and noncollagenous proteins [24]. Here neovessels 
account for ~60% of the early granulation mass [18] with vessel density 
exceeding that of uninjured tissues by more than 3-fold [19]. The delivery of 
oxygenated blood gives newly formed translucent granulation tissue its bright 
red colour, which is a predictive index for the subsequent healing of chronic 
wounds [37-40]. As 98% of wound oxygen is consumed by neutrophils to kill 
bacteria [41], the initially overshooting angiogenesis ensures the delivery of 
oxygen and cellular traffic, required for collagen synthesis and maturation, and 
also aerobic respiration to generate ATP which powers the mechanobiological 
activity of fibroblasts during contraction and compaction of collagen fibers. 
 
2.2.2 Fibroblast infiltration and proliferation 
 
With the concurrent increase in angiogenesis, fibroblasts begin to accumulate 
in the granulation tissue, accounting for ~30 to 40% of the early wound cells 
[42]. Fibroblasts are typically identified by their spindle-like morphology and a 
positive expression of vimentin, an intermediate filament in mesenchymal cells 
[43]. Fibroblasts not only originate from resident fibroblasts in the adjacent non-
wounded dermis [44,45], but also arises from blood vessels. This was first 
observed by Geoffrey Hadfield (1963) in granulation tissue of rodent wounds ~3 
days post-wounding. Here vessels were seen widely dilated, with fibroblastic 
cells in the perivascular sheaths leaving the vascular plexus and migrating into 
the wound stroma [46]. Subsequent studies identified that these fibroblast-like 
cells are pericytes, fibrocytes, adventitial cells and bone marrow mesenchymal 
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stem cells [47,48]. These fibroblasts of heterogenous origins rapidly proliferate 
in the presence of growth factors and cytokines secreted by platelets, 
macrophages, lymphocytes and endothelial cells (ECs) [44]. The activity of 
many of these growth factors e.g. platelet-derived growth factor (PDGF), Insulin 
growth factor 1 (IGF-1), transforming growth factor beta 1 (TGF- β1) rely on 
redox-signaling [49,50] which is supported by an oxygenated blood supply.  
 
2.2.3 Collagen synthesis and deposition by fibroblasts  
 
In early granulation tissues, fibroblasts synthesise fine and randomly oriented 
collagen type III fibrils, increasing the synthesis of collagen type I fibrils as the 
granulation tissue matures [24]. Importantly, the conditions for collagen 
synthesis and maturation can only proceed if oxygen is available to be 
incorporated into the structure of nascent collagen by the enzymes prolyl 4-
hydroxylase, lysyl hyroxylase and lysyl oxidase [51]. During collagen synthesis, 
prolyl hydroxylase inserts an oxygen atom into selected prolines of procollagen 
peptides, converting them to hydroxyprolines. This allows for collagen to be 
exported extracellularly. Thereafter lysyl hyroxylases hydroxylate lysines in the 
collagen molecule to cross-link collagen monomers into collagen fibrils. Lysines 
that become stable covalent links in the collagen structure are further 
condensed by lysyl oxidases to polymerize collagen.  
 
With oxygen-dependent enzymes required for collagen synthesis and 
maturation, it is thus not surprising that the rate of collagen deposition is 
proportional to the wound oxygen tension (pO2) [52]. Here collagen deposition 
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is 0 when pO2 = 0, at half-maximal when pO2 = 25 mmHg and at maximal velocity 
when pO2 exceeds 200 mmHg [51]. In ischemic diabetic wounds, pO2 ranges 
only beween 4 to 11 mmHg [53], correlating to the sparse collagen deposition 
in the wound [54]. As such, the intially overshooting angiogenesis is critical to 
support collagen deposition in the granulation tissue.  
 
2.2.4 Differentiation of fibroblasts into myofibroblasts  
 
Approximately 5 days post-wounding, fibroblasts begin to develop a contractile 
phenotype by differentiating into smooth muscle-like fibroblasts called 
myofibroblasts [55], reaching a maximal density between day 16 and day 31 
[56]. The contribution of myofibroblasts to contraction was first discovered by 
Gabbiani and colleagues in 1971 [57]. They were found to differentiate upon 
exposure to transforming growth factor-β(1) (TGF-β)  or a high matrix elastic 
modulus beyond ~20,000Pa [55,58]. Interestingly, proliferating ECs support this 
differentiation by secreting connective tissue growth factor [35,59,60] which 
activate the downstream TGF-β effect in fibroblasts [61-64].  
 
Compared to fibroblasts, myofibroblasts have a more extensive network of 
cytoplasmic stress fibers with large focal adhesion sites [65]. These cytoplasmic 
stress fibers are made up of microfilaments; actin and myosin II, wherein the 
predominant actin form is α-smooth muscle actin (α-SMA).  α-SMA is frequently 
used to discriminate myofibroblasts from fibroblasts; and has been found in vitro 
to confer a 2-fold increase in cell contractility compared to α-SMA negative 
fibroblasts [35]. Interestingly, a recent study by James Tomasek’s group have 
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also indicated that the α-SMA negative fibroblasts can also upregulate other 
muscle actin isoforms to increase their contractile ability upon exposure to TGF-
β [66]. 
 
Importantly, the sliding action of actin–myosin filaments is crucial in generating 
tension in collagen fibrils [35]. Myofibroblasts can adopt a combination of i) 
strong and far-ranging isometric contractions to shorten the fibril, and also ii) 
weak but repetitive subcellular contractions to straighten out the slack region of 
the fibrils [67].  These locally contracted fibrils can be proteolytically processed 
and/or stabilised by addition of new extracellular matrix (ECM) and crosslinks 
[67]. Once remodelled, the fibres can again bear mechanical load and 
myofiroblast are able to re-spread. This ultimately results in stabilised 
granulation matrix contraction, which is in contrast to the reversible and short-
lived contraction of striated smooth muscles [17]. 
 
To a great degree, this cellular contractile event is supported by a robust delivery 
of oxygenated blood supply. Aerobic cellular respiration generates abundant 
adenosine triphosphate (ATP) needed for sustained myosin ATPase 
(adenosine triphosphatase) activity [17]. As such, the lack of oxygen was 
demonstrated by Boris Hinz’s group to result in the reversible disassembly of α-







2.2.5 Fibroblast tractional forces  
 
Another mechanism by which the granulation matrix is condensed is through 
fibroblast tractional forces [17]. Here tractional forces are likened to that of a 
moving thread on the military tank; whereby collagen sites attached to the 
surface of the fibroblast are pulled over that surface [69]. This tractional force is 
driven by the oxygen-dependent rapid sliding and relaxation of actin-myosin 
cytoskeleton microfilaments [17]. Here, fibroblasts do not buckle/contract. 
Instead, they adopt an elongated shape to minimize flexibility in order to 
translocate collagen fibrils [70].  As the collagen fibrils are rapidly translocated 
over the cell surface, they come into contact with other collagen fibrils and self-
assemble into an ordered cross-striated structure.  The aforementioned oxygen-
dependent enzyme, lysyl oxidase, then progressively compacts collagen fibers 
by eliminating water between fibrils [17].  
 
2.2.6 Wound contraction terminates 
 
The concerted events of  
i) fibroblast infiltration and proliferation,  
ii) collagen synthesis and deposition,  
iii) myofibroblast contractile forces, and  
iv) fibroblast tractional forces,  
result in the compaction of granulation matrix. This provides a driving force that 
pulls the perilesional skin into the centre of the wound (contraction). It is thus 
presumed that wound contraction terminates with a reduced effectiveness of 
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forces generated by (myo)fibroblasts [71]. Here the increasing collagen 
interconnectivity and fibril stability, renders collagen translocation less 
susceptible by the fibroblast [70]. Also as angiogenesis decreases in mature 
granulation tissues, the population of fibroblasts and myofibroblasts decreases 
by apoptosis [70,72]. Ultimately, the granulation tissue is replaced by a collagen-
rich scar tissue wherein collagen fibers are spatially oriented in the axis of 
(myo)fibroblasts (along which mechanical force develops). 
 
Having understood that angiognesis is crucial in wound contraction, but yet 
impaired in diabetes; it follows then that a proangiogenic strategy would be 




2.3 Process of sprouting angiogenesis 
 
2.3.1 Basic structure of blood vessels 
 
Angiogenesis refers to the blood vessel outgrowth from pre-existing ones. The 
smallest blood vessels are known as capillaries. Capillaries consist of a single 
layer of cells called endothelial cells (ECs) which are in direct contact with blood. 
ECs are connected to another EC via tight junctions. This junction regulates 
paracellular permeability [73]. Surrounding the ECs are mural cells such as 
vascular pericytes which provide vascular stability [74] (Figure 2.3). ECs 
together with mural cells synthesize extracellular matrix (ECM) such fibronectin, 
collagen IV and laminin to create a surrounding basement membrane needed 
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for structural and organizational stability [75].  Larger vessels have additional 
muscular layers constituting the vessel wall, such as the tunica media, and an 
outer connective tissue layer called the tunica adventitia containing nerves to 
regulate the vascular tone [76].  
 
Figure 2.3 Structure of capillary. (Figure reprinted from Garcia-Mendina et al. 
(2014) with permission [74]. Copyright © 2014 Elsevier.)  
 
2.3.2 Sprouting versus splitting angiogenesis 
 
There are two processes of vessel outgrowth from a pre-existing vessel: 1) 
splitting or 2) sprouting [77]. Sprouting has been far better understood, being 
first described by Ausprunk and Folkman in 1977 [78], while splitting was 
discovered more than a decade later by Burri and Tarak in 1990 [79].  Sprouting 
angiogenesis, as the name implies, is characterized by sprouts of ECs which 
grow towards an angiogenic stimulus. Sprouting angiogenesis can therefore 




Splitting angiogenesis, on the other hand, occurs when opposing vessel walls 
cave into the lumen of a capillary and establish a zone of contact called 
transcapillary pillars (Figure 2.4). Mural cells invade these pillars and lay down 
collagen fibers to increase the girth of the pillars. This results in a further 
increase in capillaries from an existing capillary bed, without a corresponding 
increase in the number of endothelial cells [80]. The control of its process still 
remains poorly understood as laborious methods are required to prove the 
presence of splitting, which involve determining the frequency of tissue pillars 




Figure 2.4 Sequence of events in splitting angiogenesis. (Figure reprinted from 
Djonov et al. (2003) with permission [81]. Copyright © 2003 Springer-Verlag.) 
 
In the context of full-thickness skin wounds, the vascular network in the dermis 
and subcutaneous tissue is lost. As such the sprouting process plays a more 
relevant role as pre-existing vessels may not be present within the wound site. 






2.3.3 Overview of sprouting angiogenesis 
 
Sprouting angiogenesis occurs typically in response to hypoxia. It occurs via a 
fixed sequence of events [82,83] (Figure 2.5): 
 (i) Selection of sprouting ECs  
(ii) Sprout outgrowth and guidance  
(iii) Sprout fusion and lumen formation, and 
(iv) Perfusion and maturation 
 
2.3.4 Tissue hypoxia drives sprouting 
 
Under normoxia blood vessels are maintained in a quiescent state, controlled 
by a fine balance of pro-angiogenic and anti-angiogenic signals. However when 
a tissue becomes hypoxic (i.e., typically below venous pO2 (40 mmHg or ~6%) 
[84]), cells within the tissue secrete angiogenic cytokines such as VEGF, tipping 
the balance in favor of angiogenesis. In granulation tissues hypoxia occurs 
approximately 2 to 4 days post-wounding [84,85].  Hypoxia was first discovered 
by Remensnyder et al. in 1968 to correlate strongly with the level of 
angiogenesis in wounded tissues of the cremaster muscle of rats [85]. 
Depending on the magnitude of hypoxia, cells can either undergo cell death or 
induce an adaptive survival response through the activation of the master 
regulator of oxygen homeostasis, transcriptional factor hypoxia-inducible factor-
1 (HIF-1). As HIF-1 activity is central to the development of angiogenesis, the 




Figure 2.5 Sequence of events in sprouting angiogenesis. (Reprinted from 




2.3.4.1 HIF-1 structure and function 
 
Figure 2.6 Basic structure of HIF-1 
 
The transcriptional factor HIF-1 was first identified by Semenza and Wang in 
1992 [86]. It is found ubiquitously expressed in mammalian cells, existing as a 
heteroduplex with an alpha subunit and a beta subunit [87]. The beta subunit is 
usually present in excess, while the alpha subunit is the limiting factor in the 
creation of a functional dimer [88].   
 
The N-terminus of the HIF-1α and HIF-1β polypeptide contains a basic helix-
loop-helix domain (bHLH) and a PER-ARNT-SIM domain (PAS) (Figure 2.6). 
Here the bHLH domain binds to specific DNA sequences (5’-RCGTG-3’) called 
Hypoxia Responsive Elements (HRE) [89]. The PAS domain, on the other hand, 
is involved in the heterodimerization of the alpha and beta subunits; and also 
their translocation into the nucleus [90,91]. 
 
Both HIF-1α and HIF-1β polypeptides also contain a C-terminal transactivation 
domain (CAD). CAD recruits HIF-1’s transcriptional co-activators, CREB-
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binding protein (CBP) and p300. Importantly, this recruitment regulated by the 
enzyme Factor Inhbiting HIF-1 (FIH) [92].  The HIF-1α polypeptide in particular, 
contains an additional oxygen-dependent degradation (ODD) domain. This 
domain, regulated by a class of enzymes: prolyl-4-hydroxylases (PHD), 
determines the degradation of HIF-1α [93].  
 
Both PHD and FIH enzymes are highly sensitive oxygen sensors [94], with an 
oxygen affinity (Km :90 - 250µM) lower than that of oxygen tensions in tissues 
[95]. Here the activity of PHD and FIH is mainly governed by 3 cofactors [96]:  
(i) dioxygen (O2),  
(ii) 2-oxoglutarate (2-OG; a citric acid cycle intermediate), and  
(iii) ferrous iron (Fe2+). 
 
When all 3 cofactors are present under normoxia, PHD and FIH actively repress 
HIF-1 activation (Figure 2.7). PHD hydroxylates the ODD domain, enabling the 
von Hippel Lindau protein (pVHL) to bind to HIF-1α thus ubiquitinating it. This 
results in its proteasomal degradation. Concurrently, FIH hydroxylates the CAD 
domain to prevent the recruitment of transcriptional co-activators CBP-p300. 
This inhibits HIF-1 transcription. 
 
Under hypoxia or in the absence of any cofactor, PHD and FIH are inactive and 
thus do not repress HIF-1 activity (Figure 2.7). The unhydroxylated ODD domain 
allows HIF-1α to escape proteolysis and accumulate in the cytoplasm. The 
stable HIF-1α then translocates into the nucleus, dimerizing with HIF-1β to 
forming the HIF-1 heterodimer. The unhydroxylated CAD domains of HIF-1 
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allows for transcriptional co-activators CBP/p300 to be recruited [97]. This HIF-
1 heterodimer complex then binds to HRE, upregulating the transcription of 
numerous HIF-1 target genes related to angiogenesis, vasomotor regulation, 
growth and apoptosis, migration, energy metabolism, matrix function, hormonal 
regulation and transcriptional regulation [98,99].  
 
In endothelial cells (ECs), HIF-1 activation upregulates approximately 245 gene 
probes with at least a 1.5 fold increase; and it also concurrently downregulates 
325 gene probes by at least 1.5 fold [100]. Figure 2.8 provides an overview of 
some of the well-known HIF-1 target genes upregulated in ECs [100,101]. 
Among the various HIF-1 angiogenic targets, vascular endothelial growth factor-
A (VEGF-A) has been the indisputable angiogenic stimulant for the selection of 









Figure 2.7 Intracellular pathways involved in the oxygen dependent regulation 




Figure. 2.8 A list of some known direct transcriptional target genes of HIF-1 




2.3.5 Selection of sprouting ECs with VEGF-A 
 
VEGF-A was first discovered by Dvorak and colleagues in 1983 [102].  It was 
found to be absent in normal skin but strongly upregulated upon injury, 
correlating temporally and spatially with the proliferation of new blood vessels 
[36,103]. In 1996, Carmeliet and colleagues demonstrated that the loss of a 
single VEGF-A allele results in defective vascular development and early 
embryonic lethality [104]. And to date, there does not appear to be redundant 
growth factor mechanisms that can replace the role of VEGF-A in angiogenesis 
[105]. Other proangiogenic growth factors such as platelet derived growth factor 
B (PDGF-B), basic fibroblast growth factor (bFGF), angiopoietin (ANG), 
transforming growth factors, apelin, and insulin-like growth factors (IGF) serve 
to complement or coordinate VEGF-A signalling rather than function as 
independent regulators of EC proliferation, migration and survival [106].  
 
In hypoxic tissues, parenchymal cells such as dermal fibroblasts are major 
producers of VEGF-A [107]. Upon HIF-1 activation they upregulate VEGF 
secretion by approximately 10-fold [21], inducing a VEGF-A microgradient 
towards the surrounding “mother” vessel. Here quiescent ECs expose to the 
highest VEGF-A concentration are selected as tip cells for sprouting [83]. Tip 
cells upregulate Delta-like 4 (DLL) signalling molecule expression and extend 
numerous filopodia into surrounding ECM in search of angiogenic cues [83]. 
They have an increased glycolytic activity and adopt a migratory phenotype, 
with limited proliferative capacity, navigating at the forefront of endothelial 
sprouts [83].  
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2.3.6 Sprout outgrowth and guidance 
 
As tip cells emigrate from the “mother” vessel, they secrete matrix 
metalloproteinases (MMP) to breakdown the basement membrane, EC-mural 
cell adhesions and surrounding extracellular matrix (ECM). MMP exposes 
cryptic proangiogenic integrin binding sites in the ECM, releases ECM-bound 
angiogenic growth factors such as VEGF-A, bFGF, IGF [108] and also anti-
angiogenic molecules to prevent inappropriate sprouting and coordinate 
branching. MMP regulation is essential for sprouting, given that excessive 
degradation of the ECM leaves too little matrix support for the branch to sprout 
[83].  
 
In order for the sprout to elongate, proliferation of ECs are necessary. As such, 
not all ECs exposed to paracrine VEGF-A will become migratory tip cells. ECs 
that acquire the tip cell phenotype, secrete DLL to activate Notch signalling in 
neighbouring ECs [83]. This suppresses the VEGF receptor 2 expression in 
neighbouring ECs, rapidly dampening their sensitivity to paracrine VEGF-A 
[109]. These cells thus adopt a stalk cell phenotype, producing fewer filopodia 
and are more proliferative following closely behind a tip cell.  
 
As endothelial sprouts elongate along the VEGF-A gradient, they transit into a 
region of hypoxia, being further away from the “mother vessel”. To support their 
metabolic requirements, the ECs’ HIF-1 activity is upregulated. This results in 
an increase in glycolysis, ATP production [100] and it also induces a VEGF-A 
autocrine loop to maintain EC proliferation and motility under hypoxia [110].  
30 
 
2.3.7 Sprout fusion and lumen formation 
 
Tip cells from two or more sprouts converge and fuse at the source of paracrine 
VEGF-A secretion. Multiple intracellular vacuoles then begin to form in the stalk 
cells. These vacuoles merge to create a continuous lumen for perfusion [82]. 
Here the size of the lumen depends on VEGF-A levels, with larger lumens form 
under higher VEGF-A exposure [111].  
 
2.3.8 Perfusion and maturation 
 
Up till this point, VEGF-A has been effective in developing newly formed 
immature vessels. Nonetheless, high concentrations of VEGF-A induces 
tortuous and leaky vessels [112]. This observation led to VEGF’s initial 
designation as the vasopermeability factor [102,113].  A functional vessel 
network requires synergism among various angiogenic growth factors. Here 
HIF-1 activated ECs release PDGF-B [114] to recruit mural cells for the rebuild 
of the endothelial basement membrane [83,115]. Platelets also release 
sphingosine-1-phosphate (S1P) [116] to increase actin lamellipodia assembly 
and N-cadherin trafficking to the ablumenal side of the ECs [83,117]. 
Collectively, these events strengthens the EC-pericyte contacts, promoting 
endothelial tight junctional integrity for a functional vessel network. As local 
tissues receive adequate perfusion, hypoxia level decreases. Correspondingly, 
the HIF-1 activity in parenchymal cells and ECs are reduced, and VEGF-A levels 
returns to normal. The stalk and tip cells return to their quiescent phenotype and 
the process of sprouting angiogenesis is now terminated. 
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2.4 Inhibitors of angiogenesis in diabetes  
 
ECs are of key importance to the tight regulation of molecular and cellular 
exchanges between the interstitial fluid and the bloodstream [420]. They do so 
by modifying the cell surface expression of adhesion molecules, such as 
integrins and selectins, and regulate molecular exchanges through paracellular 
gaps by acting on intercellular adhesion molecules from the cadherin, occluding 
and junctional adhesion molecule families [420]. Unlike other cell types, ECs 
are particularly susceptible to intracellular hyperglycemia as they are unable to 
efficiently reduce their expression of glucose transporters in the face of high 
blood glucose levels [121,122]. Intracellular hyperglycemia increases the 
expression of endothelial adhesion molecules [421], promoting the tethering, 
rolling and adhesion of circulating inflammatory cells to the endothelium. As 
inflammatory cells infiltrate and accumulate in the interstitial fluid, they release 
excessive pro‑inflammatory cytokines that further disrupt EC-EC tight junctions 
[422] causing vessels to become leaky. In addition, inflammatory cells release 
excessive proteases that degrade extracellular matrices and growth factors; and 
release excessive reactive oxygen species (ROS) that induce cell death. Here 
chronic inflammation coupled with the glycation of proteins contribute to a 
reduction in vessel density and an increase in vessel permeability in diabetic 
wounds [118, 119].   
 
This section provides a discussion on the perturbations of five biofactors which 
are herein termed as angiogenic inhibitors: 
32 
 
(i) high reactive oxygen species (ROS) levels;  
(ii) high advance glycated end products (AGEs) levels; 
(iii) low hypoxia-inducible factor-1 (HIF-1) activity;  
(iv) high matrix metalloproteinases (MMP) levels; and 
(v) low sphingosine-1-phosphate (S1P) level. 
Importantly, these angiogenic inhibitors are not mutually exclusive and would 
need to be concurrently addressed to promote a functional vasculature in 
diabetic wounds. In the course of the discussion, I will highlight a proangiogenic 
strategy, involving divalent metal chelation and S1P supplementation to combat 
these angiogenic inhibitors.  
 
2.4.1 Angiogenic inhibitor: High levels of ROS  
 
The first major angiogenic inhibitor in diabetics is the elevated level of reactive 
oxygen species (ROS) present in endothelial cells (ECs) [120]. An increase in 
intracellular glucose, results in an increased glucose oxidation in the Kreb’s 
cycle. This generates a large number of electron donors such as NADH and 
FADH2, which donates their electrons rapidly across mitochondrial membrane 
protein complexes [121]. But as these protein complexes are unable to cope 
with the high influx of electrons, the excess electrons are instead donated to 
molecular oxygen generating ROS such as superoxides. The mitochondrial 
isoform of the enzyme superoxide dismutase degrades this oxygen free radical 
to hydrogen peroxide, which can be further converted to various other forms of 




A low level of ROS acts as signaling molecules in the regulation of fundamental 
cell growth and adaptation responses. However as ROS rises beyond the cell’s 
antioxidant capacity, it damages DNA, resulting in cellular senescence and 
apoptosis [124]. Moreover a high level of ROS induces EC membrane lipid 
peroxidation and decreases nitric oxide synthesis [124]. This loss of endothelial 
nitric oxide results in dysfunctional vasodilation, increased platelet aggregation, 
increased inflammation and increased endothelial permeability (reviewed in Van 
den Oever et al. (2010)) [124].   
 
 
Figure 2.9 Generation of ROS catalysed by iron [123]. (OH●: hydroxyl radical) 
 
Iron chelators reduce ROS 
 
Strategies that supress ROS include the use of iron chelators [123], free radical 
scavengers (e.g. Vitamin E) and antioxidant enzymes (e.g. superoxide 
dismutase). Iron chelation, in particular, has been thought to be particularly 
useful for diabetics as they typically exhibit elevated serum ferritin levels 
compared to nondiabetics [125,126]. In 2009, Geoffrey Gurtner’s group 
demonstrated in vitro that the iron chelator, deferoxamine, effectively reduces 
ROS production levels in ECs cultured under hyperglycemia [127]. 
Subsequently, they delivered an intraperitoneal injection of deferoxamine in an 
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ischemic dorsal skin flap of diabetic mice and found it effective in reducing 
necrosis while promoting angiogenesis [128]. Takuji Nakashima’s group also 
discovered that the iron chelator Ciclopirox Olamine (CPX) could dose-
dependently scavenge ROS released from inflammatory cells [129]. In 2011 
Michael Longaker’s team topically applied CPX in diabetic murine wounds and 
showed that it did indeed promote endothelial cell infiltration [130]. Cumulative 
evidence thus support iron chelators as an effective proangiogenic strategy to 
suppress ROS in diabetic wounds. 
 
2.4.2 Angiogenic inhibitor: High levels of AGEs  
 
The second major angiogenic inhibitor in diabetics is an elevated level of 
advanced glycation end-products (AGEs). In particular, AGEs present in the 
diabetic skin tissue correlate closely with the severity of microvascular 
complications [124,131]. Compared to nondiabetics, diabetics have an 
approximately 5-fold increase in AGE-serum peptides [132]. Here AGEs are 
formed through a non-enzymatic glycosylation process where excess glucose 
attaches to free amino groups on proteins to form an Amadori product (Figure 
2.10a). The Amadori product rearranges into highly reactive intermediates with 
dicarbonyl groups (such as deoxyglucosone, glyoxal and methylglyoxal) which 
are capable of physically crosslinking proteins, DNA or lipids to form various 
AGEs products (Figure 2.10b) [133,134]. Similar to ROS, the formation of AGEs 
is catalysed by transitional metal ions; wherein the oxidation and reduction of 
metal ions drive the vicious cycle of dicarbonyl AGE precursor and ROS 





Figure 2.10 (a) AGEs formation: Glucose condenses with amino groups to form 
reversible Schiff base adducts. Intramolecular rearrangements results in 
Amadori products which upon further rearrangements, dehydration and 
condensation reactions result in irreversible AGEs. (b) Various structures of 
AGEs. (Figure reprinted from Bierhaus et al. with permission [136] Copyright © 
1998 Oxford University Press.) 
 
 
Figure 2.11 Vicious cycle of transition metal-driven ROS formation (hydroxyl 
radicle) and AGE precursor formation (dicarbonyl compounds). (Figure 




AGEs chemically modify and cross link tissue proteins, lipids, and DNA. This 
affects their structure, function and turnover, contributing to a gradual decline in 
endothelial function [124]. In particular, AGE-modified proangiogenic growth 
factors have an attenuated downstream signalling response [138-142]. When 
injected in nondiabetic animals, AGE-modified proangiogenic growth factor 
attenuate angiogenesis compared to the unglycated form [143]. In addition, 
AGEs reduce the rate of collagen polymerisation [144] and decrease collagen’s 
affinity for proteoglycans [124]. This in part contributes to an increase in 
endothelial permeability and a decrease in endothelial matrix elasticity 
[124,145]. AGEs also increase the expression of endothelial adhesion 
molecules, which in turn promotes the interaction of the endothelium with 
inflammatory cells [144].  
 
Metal chelators reduce AGEs 
 
Strategies to decrease AGEs include the use of AGEs-inhibitors and AGEs-
breakers. AGEs-inihibitors, such as aminoguanidine and pyridoxamine, were 
proposed to trap reactive dicarbonyl intermediates, while AGEs-breakers such 
as alagebrium, phenacylthiazolium and phenacyldimethylthiazolium bromide 
were proposed to cleave AGEs dicarbonyl cross-links in tissue proteins [146]. 
Nonetheless their mechanism of action remains poorly understood.  
 
Cumulative evidence by John Baynes’s group indicated that both AGEs-
breakers and AGEs inhibitors in fact shared a similar working mechanism i.e., 
metal chelation [137,146]. AGE inhibitors displayed weak to potent copper 
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chelating activity while AGE-breakers had extremely strong potent copper 
chelating activity to inhibit metal-catalysed oxidation reactions involved in AGE 
formation [146]. In 2010, Yukio Fujiwara’s group discovered that an oral delivery 
of a non-specific metal chelator, citric acid, prevented AGEs formation in the 
eye lens of diabetic Wistar rats [147].  
 
These metal chelating AGE-inhibitors and AGE-breakers have also been 
reported to be effective in promoting functional blood vessel development in 
various diabetic models. In 1999, Teixeira et al. found that an intraperitoneal 
treatment of the AGE-inhibitor aminoguanidine in diabetic rats promoted 
pericytes and vascular cell infiltration into subcutaneously implanted sponge 
granuloma [148,149]. The same aminoguanidine was later found to be effective 
in reducing skin flap necrosis in diabetic rats [150]. The AGE-breaker 
phenacylthiazolium was found by Daniel Herion’s group to improve 
endothelium-dependent dilation in a mesenteric ischemia diabetic rodent model 
[151], while Bruce Wolffenbuttel’s group also demonstrated that the AGE-
breaker alagebrium reversed carotid artery stiffness in diabetic rats [152]. 
Cumulative evidence thus indicate that metal chelators are effective in 










2.4.3 Angiogenic inhibitor: Low HIF-1 activity  
 
The third major angiogenic inhibitor in diabetics is low hypoxia-inducible factor-
1 (HIF-1) activity [153,154]. The transcriptional factor HIF-1 is an upstream 
regulator of numerous target proteins involved in angiogenesis (§2.3.4). Its 
impaired activity has been attributed to a particular AGEs precursor – 
methylglyoxal [155]. Methylglyoxal forms stable adducts with HIF-1’s subunit – 
HIF-1α, and impairs its activity in three ways. Firstly, it reduces HIF-1α’s 
capacity for heterodimerization with HIF-1β. Secondly, it increasing HIF-1α’s 
degradation by promoting HIF-1α’s association with heat shock protein 40/70 
[155]. Thirdly it covalently modifies HIF-1’s transcription co-activator p300 
thereby suppressing HIF-1’s transcriptional activity [156]. Collectively, these 
effects attenuate various HIF-1 downstream gene expressions (e.g. VEGF, 
bFGF, eNOS and glycolytic enzymes), reducing the migration of endothelial 
cells (ECs) [94,128,153,156-158].  
 
Iron chelation reverses HIF-1 activity impairment  
To increase HIF-1 activity, iron chelators have been proposed. Here iron 
chelators work via a two-pronged approach. Firstly, it curtails methylglyoxal 
formation as iron is a catalyst for methylglyoxal AGEs precursor formation [128] . 
Secondly, it inhibits HIF-1α subunit degradation [159] as Fe2+ is a cofactor for 
prolyl hydroxylases that continuously earmark the HIF-1α for proteasomal 
degradation. Cumulative evidence have demonstrated the angiogenic efficacy 
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*Specificity (IC50) for prolyl hydroxylase (PHD) or Factor Inhibiting HIF-1 (FIH). 




2.4.4 Angiogneic inhibitor: High MMP levels 
 
The fourth angiogenic inhibitor in diabetics is the overexpression of matrix 
metalloproteinases (MMPs). MMPs are a group of zinc- or calcium-dependant 
proteolytic enzymes, which are collectively endowed with the capability of 
degrading all extracellular matrix (ECM) proteins [163]. MMPs play an important 
role in angiogenesis by (i) degrading vascular basement membrane and ECM 
components to allow detachment of pericytes and endothelial cell (ECs) 
migration; (ii) localizing MMP-2 to the invading edge of EC to aid migration; (iii) 
exposing cryptic integrin binding sites from cleaved ECM molecules; and (iv) 
releasing and activating angiogenic growth factors stored in the ECM [169].  
 
In normal physiological angiogenesis there exists a tightly-controlled balance 
between MMP activity and MMP inhibitors (reviewed in Rundhaug (2005)) [169]. 
However in diabetic wounds this balance is perturbed, with overexpression of 
collagenases; MMP-1 (65-fold), MMP-8 (2-fold) and gelatinases; MMP-2 (6-fold) 
and MMP-9 (14-fold) compared to nondiabetic traumatic wounds [164]. 
Moreover, MMP elevation in diabetics exists even prior to wounding [165]. Such 
prolonged overactivity of MMP often results in ‘off target’ destruction of ECM 
proteins, proangiogenic growth factors and their ligand binding domains [170]. 
In human chronic wound fluid, a 30-fold increase in total MMP activity is 
associated with a proportionate increase in epidermal growth factor degradation 
[171]. Diabetics also typically exhibit elevated levels of collagen degradation as 
evidenced by an increase urinary hydroxyproline content [172]. This increase in 
collagen degradation releases abundant anti-angiogenic collagen chain 
fragments such as endostatin, tumstatin, arrestin and canstatin.  Exposure to 
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these anti-angiogenic fragments induces EC apoptosis and inhibits VEGF and 
bFGF-induced EC migration [169,173]. 
 
Zinc chelators reduces MMP activity 
 
The pathophysiological pathway of the elevated MMPs in diabetics remains 
unclear. Recent evidence suggests a possible link between high ROS and high 
MMPs levels mediated by the transcription factor NF-κB [166-168]. Current 
efforts to downregulate MMP activity include the use of small-molecule mimics 
of MMP substrates combined with a hydroxamic acid zinc-binding group that 
chelates the catalytic Zn2+ ion (reviewed in Jacobsen et al. (2010)) [174]. These 
inhibitors are potent, inhibiting all MMP subtypes. However the broad spectrum 
MMP inhibitor (ilomastat) was first tested in nondiabetic models of rodent, 
porcine and human wounds. The result was a delay in wound closure [175-177]. 
Some thus assumed that broad inhibition of MMP may also be detrimental for 
diabetic wound healing [177], and began designing specific MMP inhibitors 
[174]. In 2015, Mayland Chang’s group found that selectively inhibiting 
gelatinases (MMP-2 and MMP-9) and membrane type MMP-14 enhanced 
angiogenesis and wound closure in diabetic murine wounds [178]. Nonetheless, 
it is not known if a broad spectrum of MMP inhibition does indeed result in 







2.4.5 Angiogneic inhibitor: Low S1P levels  
 
The fifth angiogenic inhibitor is a low plasma level of lysosphingolipid: 
sphingosine-1-phosphate (S1P). S1P was discovered in 1991 by Sarah 
Spiegel’s group [180]. It is intracellularly derived from the phosphorylation of 
sphingosine, a cell membrane lipid molecule [181]. It can be exported 
extracellularly and carried in the blood plasma by high-density lipoprotein (HDL) 
and albumin [116,182]. Recent evidence indicates that diabetic HDL with a 
higher content of S1P exerts vasculoprotective effects as a form of the body’s 
compensatory mechanism to prevent or delay diabetic complications [179]. 
Here severe diabetics were found to exhibit a reduced HDL-S1P level compared 
to early stage diabetics [179]. Nonetheless, its pathophysiological pathway 
remains unclear. Some evidence suggests a high ROS levels as a cause, 
degrading a key enzyme involved in S1P synthesis i.e., sphingosine kinase 1 
[197]. Other evidence indicates an association between AGEs and S1P levels 
[198].  
 
The vasculoprotective effects of S1P are exerted through G-protein coupled 
S1P receptors [183]. ECs express three G-protein coupled S1P receptor 
subtypes: S1P1, S1P2, and S1P3 [184]. S1P1 and S1P3 has been proposed to 
be  the major receptors mediating angiogenesis [185,186],  while the role of 
S1P2 in angiogenesis remains unclear as conflicting studies indicate both 
proangiogenic and anti-angiogenic effects of S1P2 [187,188]. Histological 
analysis of S1P1 knockout mice revealed that S1P1 signalling is not essential 
for EC differentiation, proliferation, migration or tube formation [189]. However 
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its deficiency resulted in defective migration of mural cells (vascular smooth 
muscle cells and pericytes) around nascent blood vessels leading to severe 
haemorrhaging and death in-utero [189,190]. Numerous studies have also 
established that S1P1 signalling enhances actin lamellipodia, actin assembly, 
vascular endothelial cadherin-containing adheren junctions between EC-EC 
and also N-cadherin-dependent junctions between EC-pericytes [189,191-195]. 
S1P1 activation also enhances the EC-EC adheren junctions by suppressing 
the expression of endothelial adhesion molecules [420]. Its suppression reduces 
the interaction between inflammatory‑cells with the endothelium; and hence 
there will be less infiltration of inflammatory cells and consequently less 
proinflammatory cytokines, which is a major cause for EC-EC tight junction 
disruption.  
 
As mentioned above, S1P is not necessary for EC migration. However, its 
presence accelerates EC migration which is mediated through both S1P1 and 
S1P3 signalling [186]. S1P3 signalling also promotes vasodilation by increasing 
EC nitric oxide production [196].  
 
S1P supplementation promotes functional non-leaky vasculature   
 
Current evidence indicates that direct supplementation of S1P or its synthetic 
analogue, FTY720 is efficacious in promoting functional non-leaky vasculature. 
In nondiabetic mice, Timothy Hla’s group reported that oral delivery of FTY720 
effectively reversed VEGF-induced vasculature permeability [200]. In diabetic 
rats, intraperitoneal injection of FTY720 (1mg/kg) was also seen to reverse the 
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permeability of inter-endothelial clefts and albuminal surface in the cardiac 
microvasculature [201]. In vitro, FTY720 blocked VEGF-induced internalization 
of VE-cadherin to promote EC-EC tight junctions formation, and augmented 
endothelial barrier transmonolayer electrical resistance in a hyperglycaemic EC 
culture [191].  In diabetic mice, Yoshinao Soma’s group reported that topical 
delivery of 100 µM S1P increased angiogenesis and wound closure [199]. 
 
2.4.6 Proangiogenic strategy: Metal chelation + S1P 
 
 
Figure 2.12 Summary of angiogenic inhibitors and treatments 
 
To conclude §2.4, the current literature indicates that: (i) high ROS, (ii) high 
AGE, (iii) high MMP, (iv) low HIF-1 activity and (v) low S1P are major angiogenic 
inhibitors in diabetics (Figure 2.12). Accordingly, I have identified that metal 
(iron, copper, zinc) chelation is a common solution to tackle causes (i) to (iv). 
This treatment has an added utility in diabetics as they typically exhibit elevated 
serum levels of zinc, copper, and iron [125,202]. To tackle cause (v), a direct 
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supplementation of S1P was seen to be effective. Thus the literature suggests 
that combination of a broad spectrum metal chelator and S1P would be a 
good proangiogenic strategy in diabetic wounds.  
 
2.5 In the market: FDA-approved proangiogenic 
drugs 
 
FDA, the drug regulatory agency for the largest current pharmaceutical market 
in the world, has approved three groups of adjuvant proangiogenic therapies for 
diabetic wound healing: (i) biological matrices, (ii) modalities and (iii) drugs 
[203]. The clinical efficacy of all three groups of adjuvant proangiogenic 
therapies has been comprehensively reviewed by Greer and colleagues [205], 
and the consensus remains that there is no gold standard adjuvant treatment 
for diabetic wound closure; wherein the treatment is easy to apply and remove, 
causes no pain, is cost effective, has no complications, and allows for 
universally complete healing outcomes under various patient parameters [206]. 
Under drug therapies, only two proangiogenic drugs have been approved: (i) 
platelet-derived growth factor-B homodimer (PDGF-BB) and (ii) platelet rich 
plasma gel (PRP) [204]. In this section, I discuss the efficacy of both these 
proangiogenic drugs. A discussion on the efficacy of biological matrices and 





2.5.1 Recombinant platelet-derived growth factor-BB 
 
Recombinant PDGF-BB (generic name: Becaplermin, trade name: Regranex, 
Systagenix Wound Management Inc., Gargrave, UK) was the first 
proangiogenic drug approved by FDA in 1998 for diabetic ulcers. PDGF-BB is a 
hypoxia-inducible factor-1 (HIF-1) downstream growth factor (Figure 2.8) that 
supports neovessel stabilization by recruiting mural cells to induce functional 
anastomoses (§2.3.8). It also promotes fibroblast proliferation [207]. When 
topically applied onto diabetic murine and human wounds [211-213], PDGF-BB 
accelerated angiogenesis, granulation tissue formation, wound contraction and 
re-epithelialization [208-210]. Nonetheless, it has not been equivocally 
translated into daily practice [8]. Clinical results from more than 7000 patients 
revealed a modest 10% increase in the rate of diabetic healing with PDGF-BB 
[214], with some trials indicating that recombinant PDGF-BB was was only as 
effective as that of standard care or moist treatment with sodium 
carboxymethylcellulose gel [205]. The lack of efficacy is believed to be 
contributed by high levels of MMP in wound fluids, which rapidly degrades 
PDGF-BB [8]. Increasing its dosage to compensate for high degradation rates 
poses a risk of skin malignancy [215,216]. In 2008, FDA issued a black box 
warning following a post-market epidemiologic study linking the use of more 
than three tubes of Becaplermin to a fivefold increased risk of mortality in 
patients with a history of malignancy [217]. In 2012, Becaplermin was withdrawn 





2.5.2 Platelet rich plasma gel   
 
Autologous platelet rich plasma gel (PRP) (AutoloGel System, Cytomedix Inc, 
Rockville, MD) is the second proangiogenic drug that the FDA approved in 2007 
for diabetic ulcers. PRP contains a high concentration of platelets in a small 
volume of plasma. It works by the degranulation of the α-granules in platelets, 
which releases proangiogenic growth factors such as PDGF, TGF-β, VEGF, 
EGF and IGF [219]. PRP is derived from a two-step process: (1) centrifugation 
of whole blood from the patient to separate the plasma from red blood cells; and 
(2) centrifugation of plasma to separate PRP from platelet-poor plasma [219]. 
Hereafter, PRP is activated with thrombin or calcium to result in a gelatinous 
platelet gel [219]. Upon activation, α-granules secrete proangiogenc factors with 
more than 95 percent of the presynthesized growth factors secreted within 1 
hour [220]. Following this initial burst release, platelets continue to synthesize 
and secrete additional proteins for the balance of their lives (5 to 10 days) [220].  
 
When used in various diabetic animal models of hind-limb ischemia [221] and 
full-thickness wounds [222], PRP was efficacious in promoting angiogenesis 
and wound closure. However, its efficacy remains debatable in clinical studies 
[205, 223-224]. When compared against saline gel, PRP significantly decreased 
the diabetic ulcer size [224]. However this did not translate into a significant 
increase in the mean time to healing, nor an increase in percentage of ulcers 
healed [205,224]. Interestingly, Kakagia et al. highlighted that PRP’s efficacy in 
decreasing diabetic ulcer size was significantly potentiated when combined with 
a protease-modulating biomaterial [225]. It thus becomes clear that future 
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successful treatments will require strategies that concurrently address the multi-
factorial dysfunctions in the diabetic wound environment.  
 
2.5.3 A need for a new proangiogenic drug approach 
 
In summary, the current clinical approach in directly delivering a single or a 
combination of angiogenic growth factors for diabetic wound healing faces 
several major limitations. Firstly, supraphysiological doses of growth factors are 
required for efficacy due to (i) the short serum half-life of growth factors [226], 
(ii) the failure to supress overactive protease activity, and (iii) the failure to 
reverse an impaired HIF-1 activity (a major driver for pro-angiogenic stimulants). 
Secondly, the high doses required for efficacy leads to an increase risk of 
malignancy. Thirdly, delivery of single angiogenic growth factors may be 
insufficient for a mature and functional vascular network and can in some cases 
result in deregulated proliferation of ECs forming haemangiomas and vascular 
lacunae [227].  
 
My proposed proangiogenic strategy involves combining metal chelation and 
sphingosine-1-phosphate (S1P). As discussed in §2.4.6, this strategy seeks to 
address the multifactorial angiogenic inhibitors in the diabetic wound 
environment. Here metal chelation aborogates the need for supraphysiological 
doses of growth factors by (i) suppressing matrix metalloproteinases (MMP) 
activity to reduce growth factor degradation, and (ii) reversing the impaired HIF-
1 activity to induce physiological release of a variety of proangiogenic 
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stimulants. Complementarily, S1P supplementation promotes a mature and 
functional vascular network.  
 




The high research and development costs are not unique to the field of wound 
repair [230]. Despite the billions of dollars poured in by pharmaceutical 
companies yearly for de novo drug discovery, very few drugs tested enter the 
market [230]. In fact, there has been a paucity in FDA’s new drug approval over 
the last 10 years [228,229] (Figure 2.13). If the new drug successfully emerges 
from regulatory channels and clinical trials, time becomes the enemy [230]. 
Here, the process of acquiring adequate data to support drug approval typically 
requires 10 to 15 years. By then patent protection can lapse and generic 
competitors begin to take a large portion of the market share [230, 231]. At the 
end of the process, the high pricing of new drugs become a financial constraint 
for caregivers. Thus to reduce the cost, reduce the time-frame for drug approval 
and to increase success rates, drug repurposing and drug synergy approaches 
are favoured [232].  
 
Drug repurposing is a process of finding new uses of existing drugs. Here drug 
repurposing leverages on established clinical drug libraries of pharmacology, 
formulation development, potential toxicity and bulk manufacturing process to 




Figure 2.13 Paucity in new molecular entity (NME)/ new biological entity (NBE) 
approvals despite rising research and development (R&D) expenditures. 
(Figure reprinted with permission from Tufts CSDD; PhRMA, 2014 Industry 
Profile [228]. Copyright © 2014 Tufts CSDD.) 
 
Drug synergy, on the other hand, involves the identification of drug pairs that 
creates a greater effect than the sum of the individual drug’s effect [233]. Here 
drug synergy can result when one drug's action helps another drug's availability 
in the target cells, either by increasing the second drug's entry to the cell or by 
decreasing the second drug's degradation [234]. Drug synergy can also occur 
when drugs target the products of genes that act in parallel pathways. Although 
in vitro identification of drug synergy is rare (4–10%) [235], various methods to 
predict synergistic drug combinations have been developed. They include 
network analysis of expression profiles, clustering of chemogenomic profiles of 
drug perturbations [236] and screening of drugs in three-dimensional 





2.6.2 Repurposing and sprouting synergy of CPX and S1P 
 
A three-dimensional microfluidic platform that screens angiogenic drugs which 
induces endothelial cell (EC) sprouting was established in 2013 by Roger 
Kamm’s group (Singapore MIT Alliance for Research and Technology) [21]. In 
their platform (Figure 2.14), human umbilical vein ECs and IMR-90 fibroblast 
are separated by a collagen channel. ECs are allowed to sprout through the 
collagen gel towards the microgradient of angiogenic factors released by 
fibroblasts. Fibroblasts, on the other hand, are encapsulated in alginate beads 
unable to migrate into the collagen gel. Using this platform, a colleague in my 
lab assessed the efficacy of EC sprouting under mono or combinatory treatment 
of drugs: ciclopirox olamine (CPX) and sphingosine-1-phosphate (S1P).  
 
Here S1P and CPX are clinically used for different purposes. S1P is a 
lysophospholipid whose analogue (Fingolimod, code name FTY720) has been 
FDA-approved as an oral drug for multiple sclerosis since 2010 [237]. CPX is 
an off-patent synthetic antifungal drug discovered in the late 1960s [238]. It has 
been FDA-approved in multiple anti-fungal topical formulations as 0.8% CPX 
(Batrafen®) for skin and shampoo and 8% CPX in nail lacquer [239]. CPX is 
highly lipophilic, penetrating the deep layers of the skin easily and can be safely 
eliminated in the form of glucuronides [238]. Importantly, CPX is a metal chelator. 
It chelates divalent metal cations (Mg2+, Ca2+, Cu2+, Fe2+, Zn2+ and Mn2+) with 
high affinity [240]. In 2003, CPX was serendipitously identified by Roger 
Wenger’s group [241] as an inhibitor of HIF-1α degradation by chelating Fe2+, a 
cofactor for the prolyl and arginyl hydroxylases that continuously earmark the 
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HIF-1α subunit for proteasomal degradation. They further demonstrated CPX’s 
angiogenic effect in a chick embryo chorioallantoic membrane assay [241].  
 
As an extension to their findings, my lab discovered that the combination of CPX 
and S1P potentiated the number of sprouting ECs and its sprout length [21,242]. 
Of the maximal sprout length formed, S1P alone increased sprout length by 
~150 µm as compared to control, while CPX alone increased sprout length by 
~60 µm as compared to control (Figure 2.14). Notably, their combination 
increased sprout length by ~290 µm, which exceeds the effects of either agent 
alone or their additive effects (e.g., 150 µm + 60 µm = 210 µm, which is less 
than 290 µm). This demonstrates a synergistic angiogenic effect. Moreover 
under confocal microscopy, the sprouts growing towards the encapsulated 
fibroblast were found to exhibit lumina of approximately 30 µm in diameter 
(Figure 2.15).   
 
Since no other metal chelator has been reported to synergistically promote 
endothelial sprouting with S1P, I have thus decided to use the combination of 





Figure 2.14 In a 3D microfluidics platform, 8 µM CPX+ 250 nM S1P 
synergistically increased human umbilical vein endothelial cell (HUVECs) 
infiltration and sprout length in the presence of fibroblasts (IMR-90). HUVECs 
seeded in the left channel, sprout through a collagen gel towards IMR-90 cells 
trapped within the right channel. Horizontal red bars, in the bright field images, 





Figure 2.15 In combination, CPX and S1P induced vascular network structure 
with defined lumina. (a) Stitched; (b) and (c) sectioned 20x confocal image of 
CPX+S1P induced vascular network stained with Hoechst (blue), phalloidin 
actin (red) and VE-cadherin (green) shows sprouts that anastomose. White 
arrows indicate lumina of endothelial sprouts with diameters of ~30 µm. (Figure 













Chapter 3                             









3.1 Hypothesis 1:                                               
CPX+S1P potentiates HIF-1 activity in vitro 
 
3.1.1 Rationale for assessing HIF-1 activity in endothelial cells  
 
Hypothesis 1 seeks to assess if CPX+S1P potentiates HIF-1 activity in vitro. 
Here I have chosen to use endothelial cells (ECs), more specifically human 
umbilical vein ECs (HUVECs), as the in vitro cell type to be assessed. 
Compared to other cell types like fibroblasts, ECs are not known to be the 
biggest producers of angiogenic growth factors [21]. Nonetheless their autocrine 
production of proangiogenic stimulants are vital for angiogenesis. In 2004, Tang 
et al. ablated HIF-1α in murine ECs to disrupt their autocrine production of 
vascular endothelial growth factor-A (VEGF-A) [110]. They demonstrated in vivo 
that this ablation inhibited EC proliferation, chemotaxis and extracellular matrix 
penetration inspite of exposure to VEGF-A [110]. Morever HIF-1α’s ablation in 
EC impaired murine wound closure [110].  In 2006, Calvani et al. discovered 
that the HIF-1α-induced bFGF autocrine loop in ECs was necessary for the 
survival and sprouting of hypoxic ECs [101]. Overexpressing HIF-1α in ECs was 
separately shown in vitro to potentiate its invasion into an environment with 
abundant proangiogenic growth factors [100].   
 
In Hypothesis 1, I assessed the HIF-1 activity in ECs under an exposure to mono 
and combinatory treatment of CPX and S1P. Here HIF-1’s activity is assessed 
through a two-pronged approach. Firstly, through the upregulation of two of HIF-
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1’s upstream activators: (i) HIF-1α and (ii) phosphorylated p42/44 MAPK 
[243,244]. Secondly, through the upregulation of three of HIF-1’s downstream 
angiogenic targets [245]: (i) VEGF-A, (ii) c-MET (Hepatocyte growth factor 
receptor) and (iii) eNOS (endothelial nitric oxide synthase). 
 
3.1.2 Culturing HUVECs  
 
Primary human umbilical vein endothelial cells (HUVECs) were kindly provided 
by Dr. Jerry Chan (KK Hospital, Singapore), harvested in accordance with 
Domain Specific Review Board of National Healthcare Group. HUVECs were 
plated in cell culture flasks precoated with 50 µg/ml rat tail collagen I solution 
(BD Biosciences, San Jose, CA) in 0.02 M acetic acid (VWR, Radnor, PA) and 
maintained in endothelial growth medium (EGM; Lonza, Walkersville, MD) until 
80% to 90% confluent. HUVECs were used at passage 5 to 6. 
 
3.1.3 Preparation of CPX and S1P solution 
 
10 mM ciclopirox olamine (CPX) (Sigma, St. Louis, MO) stock solution was 
prepared in dimethyl sulfoxide and diluted to 1- 40 µM working solution in culture 
media. S1P powder (Sigma) was dissolved in methanol:water (95:5) at 0.5 
mg/ml under sonication. Solvent was evaporated at 55°C in a water bath to 
render a thin film of S1P to be stored at -20°C [21].  4 mg/ml of fatty acid-free 
bovine serum albumin (Sigma) in phosphate-buffered saline was the diluent to 
make a 125 µM S1P stock [21]. The final S1P concentration in the culture media 
was 0 - 0.2 μM. 
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3.1.4 Immunoblotting  
 
80 000 HUVECs were seeded into 6-well plates (Greiner Bio-One, 
Frickenhausen, Germany) in EGM (Lonza) and allowed to adhere for 24 hours. 
Thereafter EGM was removed, cells were washed with Hanks’ balanced salt 
solution (Thermo Fisher Scientific) and then treated with 0 – 40 μM CPX or 0 -
0.2 μM S1P in endothelial basal media (Lonza) supplemented with 5% FBS 
(Thermo Fisher Scientific) at 37°C with 5% CO2. The HUVEC monolayer was 
lysed 1 to 8 hours after treatment with 100 ul of sodium dodecyl sulfate (SDS) 
sample buffer containing the phosphatase inhibitors aprotinin, leupeptin, and 
pepstatin at 10 µg/mL each (R&D Systems, Minneapolis, MN). Protein 
concentration was determined by Bradford assay (Thermo Fisher Scientific) and 
20 µg of total protein per sample was loaded into 10 % resolving / 3 % stacking 
or 12 % resolving / 5 % stacking SDS PAGE gels, electrophoresed and 
transferred to nitrocellulose membranes (Biorad, Hercules, CA) for 1 hour at 100 
V. Membranes were blocked with 5% bovine serum albumin and incubated with 
primary rabbit polyclonal antibodies: HIF-1α (1:1000 dilution, GeneTex, Irvine, 
CA), VEGF-A (1:500 dilution, Abcam, Cambridge, MA), c-MET (1:1000 
dilution,Thermo Fisher Scientific), eNOS (1:1000 dilution, Cell Signalling, 
Danvers, MA, USA), phosphorylated p42/44 MAPK (1:1000 dilution, Cell 
Signalling) and primary mouse monoclonal antibody β-Actin (1:2000 dilution). 
Secondary antibodies goat anti-rabbit HRP and goat anti-mouse HRP (1:2000 
dilution) were from Dako (Agilent, Santa Clara, CA). Bound antibodies were 
detected with Supersignal West Pico or Femto Chemiluminescent substrate 
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(Thermo Fisher Scientific). Chemiluminescence was quantified using ChemiDoc 
XRS (Biorad). 
 
3.2 Hypothesis 2:                                                
CPX+S1P potentiates angiogenesis in vivo 
 
3.2.1 Rationale for using sponge implant model  
 
Hypothesis 2 seeks to assess if CPX+S1P potentiates angiogenesis in vivo. 
There are variety of in vivo angiogenic models which has been well reviewed by 
Staton et al. (2009) [251]. Their advantages and limitations are highlighted in 
Table 2. The choice in vivo model should be one that reflects reality, where 
reality is defined in terms of applicability to patient treatments and the relevance 
to the site of evaluation [305]. The ‘gold standard’ angiogenic model is often 
cited as the corneal assay system [305], because angiogenesis occurs in an 
apparently neutral site and its response is easily documented throughout the 
induction period. Nonetheless, the concept of ‘neutral’ is paradoxical as blood 
vessels normally do not grow in this avascular site and the cornea is a ‘privileged 
site’ i.e., protected from circulating cells, rapid immune reactions and many 
serum components [305]. Hence the angiogenic response in the cornea would 
be different from ‘non-privileged sites’ like the skin. 
 
There are two in vivo models which are relevant for skin wound angiogenesis: 
(i) the dorsal wound chamber and (ii) the subcutaneous sponge implantation.  
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Both models allow for serial drug administrations (topical/ intra-dermal injection). 
I have chosen the subcutaneous sponge implantation over the dorsal wound 
chamber as it provides an experimental environment of defined dimensions 
where only new vessels and not existing vessels can be measured and it is also 
technically less demanding. Since 1951, when sponge implantation was first 
established by Grinlay and Waugh, many angiogenic compounds have been 
developed from this model [247-248].  
 
There are a variety of subcutaneously implanted sponges. They include 
stainless steel mesh chambers, hollow chambers with porous walls and 
synthetic sponge matrix (polyvinyl alcohol (PVA), cellulose acetate, polyester 
and polyurethane) implants [306]. These sponges induce a foreign tissue 
reaction which allow for a rapid deposition of connective tissue around the 
sponge, creating an artificial tissue space into which plasma infuses  and a fibrin 
clot is which is subsequently replaced by granulation tissue [249,250].   
 
Various angiogenic parameters can be measured from the sponge granulation 
tissue  [306]. They include  (i) the endothelial fractional area, (ii) the fraction of 
EC immunoreactive for proliferating cell nuclear antigen, (iii) the rate of blood 
flow measured by 133Xe clearance, (iv) the leakiness of vessels measured by 
fluorescein dye diffusion, (v) the amount of functional vessels measured by 
haemoglobin levels in the sponge, (vi) the length of functional vessel measured 
by FITC-isolectin perfused length and (vii) the levels of angiogenic stimulants 




In Hypothesis 2, I assessed angiogenesis in a subcutaneously implanted PVA 
sponge under a mono or combinatory intradermal injection of CPX and S1P. 
Here angiogenesis is determined using two parameters: (i) EC infiltration, and 
(ii) functional vessel length. ECs are identified with an endothelial cell specific 























Table 2. In vivo angiogenesis assays [251, 305] 
























 Simple and fast 
procedure. 
 
 Measurement of 
new, not existing 
vessels. 
  
 Allows serial 
application.  
 
 Other parameters of 
granulation tissue 
can be assessed. 
 
 Radioactive tracer 
clearance allows 











implant site.  
 

















from disc implants 







examined via  
image analysis or 
colorimetric 
detection 










 Allows serial 
application.  
 Large number of 











 Growth of new 
blood vessels on 
CAM almost 2D  
 
 Cells responding 
are embryonic. 
 


















(done on rabbits 























 Avascular cornea 
allows real time 
monitoring of  
vessel formation. 
 
































layer of dorsal 




layer of dorsal 
skin is completely 
removed, 
exposing the 
other layer, and 

























animals over 3–4 
weeks. 
 
 Allows analysis of 
identical blood 
vessels over time.  
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3.2.2 PVA sponge implant model 
 
11 Male Sprague-Dawley rats (~300 g) were anesthetized with 2-3% isofurane 
and 1 litre per minute oxygen. Using standard aseptic procedures, four 
subcutaneous pockets were prepared in the dorsum of each rat by blunt 
dissection through 1.5 cm incisions; pockets were positioned in a 3 cm x 3 cm 
square configuration, with one pocket at each corner (Figure 3.1). A single 
saline soaked PVA scaffold (1 x 1 x 0.5 cm) (Merocel, Medtronic, CT) was 
inserted into each subcutaneous pocket, and incisions were closed with 
interrupted sutures. Analgesic buprenophrine (0.05 mg/kg) and antibiotics 
enrofloxacin (5mg/kg) was subcutaneously given over 5 days. 
 
7 days post-implantation, 200 µl of drug solution was injected into the center of 
each implanted sponge. All four sponges in each rat were injected with the same 
drug.  The drug treatments were: (1) Control (vehicle): 4 mg/ml Fatty-acid free 
rat serum albumin with 1% dimethyl sulfoxide in saline solution; (2) Vehicle plus 
CPX (0.01 mM, 0.1 mM, 1 mM); (3) Vehicle plus S1P (0.001 mM, 0.01 mM, 0.1 
mM); (4) Vehicle plus CPX (0.1 mM) plus S1P (0.01mM). Drugs were injected 
on alternate days over a 14-day period. On the day of harvest 1 ml of 0.5 µg/µl 
of fluorescein isothiocyanate (FITC)-tagged isolectin from Bandeira simplicifolia 
(reconstituted in saline containing 1 mM calcium chloride) was injected through 
the tail vein. 20 min post-injection, the rats were euthanized with carbon dioxide. 
Sponges were explanted, bisected and frozen-embedded for cryosectioning. All 
animal experiments were reviewed and approved by the Institutional Animal 
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Care and Use Committee of the Biomedical Research Committee (BRC IACUC, 
protocol number 140929). 
 
Figure 3.1 Schematic illustration of 4 sites on the dorsum of a rat, where 
saline soaked PVA sponges were subcutaneously implanted. 
 
3.2.3 Immunohistochemistry for excised PVA sponges 
 
PVA samples were cryosectioned at 2 µm or 50 µm thickness (for confocal 
imaging) and fixed in ice-cold acetone for 20 minutes. After blocking non-
specific binding with 5% BSA and 10% goat serum (Dako), endothelial cell 
infiltration into the sponges was assessed with a mouse monoclonal antibody 
against rat endothelial cell antigen-1 (RECA-1) at 1:50 dilution (16 hours, Hycult 
Biotech, Uden, The Netherlands) and a secondary Alexa Fluor 594-conjugated 
goat anti-mouse antibody, cross adsorbed against rat IgG at 1:400 dilution (1 
hour, Thermo Fisher Scientific). FITC-isolectin-perfused vessels were 
visualised with rabbit monoclonal anti-FITC at 0.005 mg/mL (16 hours, Thermo 
Fisher Scientific) and a secondary Alexa Fluor 488-conjugated goat anti-rabbit 
antibody at 1:400 dilution (1 hour, Thermo Fisher Scientific). Cell nuclei were 
stained with 0.5 mg/mL DAPI in PBS. 40x magnification images were captured 
using Zeiss LSM 510 laser scanning confocal system (Zeiss, Goettingen, 
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Germany) while 4x and 20x magnification images were captured with Olympus 
IX31 microscope (Tokyo, Japan).  
 
3.2.4 Morphometric analysis of vessel length and EC 
infiltration  
 
Analysis of RECA-1 positive immunostained areas (20x magnification field of 
view) and FITC-isolectin perfused vessel length (40x magnification field of view) 
was performed using ImageJ software. To measure the perfused vessel length 
of sprouts, 3D confocal images of FITC-isolectin staining were projected onto a 
2D plane and processed as previously reported by my lab [21]: enhancing 
contrast, despeckling, smoothening through Gaussian blur, converting to binary 
image, threshold and skeletonizing with the Image J plugin: AnalyzeSkeleton. 
 
3.3 Hypothesis 3:                                                   
CPX+S1P increases diabetic wound contraction 
 
3.3.1 Rationale for using female Zucker Diabetic Fatty Rats 
 
Hypothesis 3 seeks to assess if CPX+S1P increases diabetic wound contraction 
in an animal model. Pigs are considered to have the most translational utility 
due to their similar histological and biochemical properties to human skin [261]. 
They are similar to human skin in terms of: thickness; having follicular structures 
that extend deeply into the dermis; well-developed rete ridges and dermal 
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papillary bodies; epidermal turnover time; abundant subdermal adipose tissue; 
vascular plexus; and dermal collagen arrangement [261]. However, their high 
cost for upkeep and difficulties in handling has favoured the routine use of 
smaller rodent/murine models.  
 
Type 2 diabetic rodent model chosen 
In this Hypothesis, I have chosen a type 2 diabetic rodent model, reflective of 
the current global situation where 85 - 90 % of diabetics are type 2 diabetic 
[313]. Type 2 diabetes is characterised by insulin resistance and at times may 
be accompanied by a low insulin production. This is in contrast to type 1 
diabetes which is solely characterised by a low insulin production. Table 3 
provides a list of the currently available models for type 2 diabetes.  
 
Obese Type 2 Zucker diabetic fatty (ZDF) female rats chosen 
Animal models of type 2 diabetes can be divided into two groups: obese and 
nonobese [314]. As type 2 diabetes in humans is closely associated to obesity, 
I elected to use an obese strain [314]. Obesity in animals can be induced either 
through genetic and/or dietary means. Monogenic models of obesity arising 
from a defective leptin signalling are commonly used in type 2 diabetes 
research. The leptin hormone induces satiety. Thus a leptin receptor mutation, 
exhibited in ZDF rats, results in hyperphagia and subsequent obesity [255]. In 
female obese ZDF rats, induction of diabetes also requires a high fat diet [256]. 
Here the normal lab diet (on a caloric basis usually around 26% protein, 63% 
carbohydrate and 11% fat) is replaced with a a diet where the number of calories 
from fat is increased substantially (around  58% of energy derived from fat) 
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[314]. A high fat diet induces lipotoxicity of pancreatic beta cells and skeletal 
muscle cells, which in turn supresses insulin secretion and cellular glucose 
uptake, elevating blood glucose levels [257, 258]. Not all strains of diabetic 
animal models develop diabetic complications [314]. Here I chose ZDF rats as 
they are well-established [255,259,260] to exhibit typical diabetic humans traits 
of hypertension, neuropathies, nephropathies, polyuria, polydipsy, dysfunctional 
vasodilation [315–317], leaky vessels [318], impaired angiogenesis [319] and 
impaired wound closure [20].  In particular the female ZDF rats were chosen 
over the males as they were recently reported to exhibit a more severe wound 
healing impairment than their male counterparts [20]. Females are reported to 
exhibit a more severe reduction in granulation tissue formation and elevated 
levels of wound matrix metalloproteinases (MMP-3, MMP-13) [20]. To date, the 
exact mechanism of this gender bias in wound healing is not known. 
 
Differences between human and rodent skin 
There are several differences between human and rodent skin which are 
highlighted in Table 4. A striking difference lies in their mechanism of wound 
closure. Unlike humans which heal by both contraction and re-epithelialization, 
loose-skin rodents heal mainly by extensive contraction. Thus the next section 








Table 3. Animal models of type 2 diabetes 


















 ob/ob [320] 
 db/db [321] 
 Kuo Kondo [322] 
 Yellow KK obese [323] 
 New Zealand obese [324] 
 NONcNZo10 [325] 
 M16 [326] 




 Male Zucker diabetic fatty 
[328]  
 Otuska Long Evans 
Tokushima fatty [329] 













 Non-obese C57BL/6 Akita 
mutant [343] 




 Cohen diabetic [345] 
 Goto-Kakizaki [346] 











 Spiny [333] 
 C57/BL 6J [334] 
 
RAT 
 Israeli Sand [335] 
 Female Zucker diabetic 
fatty [256] 
 Ctenomys talarum [336] 
 
MONKEY 














 Micro-pig [339] 
 
MOUSE/RAT 
 Alloxan treated [348] 














dietary obese [340] 
 
ANIMALS 
















 β3 receptor knockout [341] 
 Uncoupling protein 
(UCP1) knockout [342] 
 
MOUSE (mainly) 
 Transgenic/ knockout of genes 
implicated in insulin resistance 
(IRS-1 [351] , IRS-2, [352]  
GLUT-4 [353] ),  
lipid and glucose metabolism  
(PPARs) [354], and  
insulin secretion (GLUT-2 
[355], Glucokinase [356], IGF-
1R [357] ) 
 
RAT 
 Human islet amyloid 
polypeptide transgenic [358] 
 
Table adapted from Chatzigeorgiou et al. (2009) [262] with permission. 
Copyright © 2009 Anticancer Research USA Inc. 
 
Table 4. Differences between human and murine/rodent skin 
 
Traits Human  Rodent/ Mouse 




Epithelial architecture Rete ridges present 
 
No rete ridges 
Apocrine sweat glands Present in axilla, inguinal, 





Thick, relatively stiff, 
adherent to underlying 
tissues 
 
Thin, compliant, loose 





Present only in neck 
region as platysma 
 
Present throughout as 
panniculus carnosus 
Major method of wound 
healing 
 




Table adapted from Wong et al. (2011) [263].  
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3.3.2 Techniques to limit extensive contraction in rodents 
 
Unlike humans, rodents have (i) a loosely organized subdermal fascial plane, 
and (ii) a thin sheet of striated muscle lying between the subcutaneous fat and 
dermal layer called the panniculus carnosus. Upon injury, this rodent anatomy 
permits an extensive pulling of perilesional skin into the wound, limiting the 
wound volume for granulation tissue accumulation. Hence modeling human 
granulation tissue-driven contraction using loose-skinned rodents poses a 
challenge [264]. Current efforts to overcome extensive contraction in loose-skin 
animals are discussed in Table 5. They include the use of (i) wound sites with 
firmly anchored skin and (ii) tension off-loading devices. 
 
I have chosen to combine three surgically simple techniques of (i) wound margin 
splinting, (ii) wound depth increment and (iii) panniculus carnosus excision to 
achieve low wound contraction rates, characteristic of human diabetic ulcers. 
The technique of wound margin splinting was first used in the 1960s. Splinting 
offloads tensile forces generated within and around the wound site [265,266] 
and has been well-established to promote granulation tissue-driven contraction 
[265-267]. The second technique of wound depth increment has not been 
demonstrated in vivo to attenuate contraction. Nonetheless, a recent 
mathematical modelling study supports this notion [269]. It is also well accepted 
that deeper wounds delay granulation tissue formation; as such wound depth 
has been a crucial predictive index for diabetic foot ulcer healing [268,270]. To 
allow for wound depth variation, I have identified a dorsal fat pad in ZDF rats 




Table 5. Techniques to limit extensive wound contraction in animals [264,271]   








Rabbit ear [359] 




Healing in the 
absence of an 
underlying 
vascularized soft 
connective tissue.  
 
Granulation tissue 
composition can vary 
with different wound 
ground. 
Murine Cranial Excision [360] 
(Removal of skin from crown  
down to calvarial periosteum.) 
 
Murine tail excision [361] 
(Circumferential removal of skin 















Wound margin splinting  
(Doughnut shaped splints made from 
silicone [362]/ steel washers [363]/ 
PDMS [364] fixated on perilesional 
wound by gluing and suturing.) 
Mutilation of soft splints 
with self-grooming. 
Require rat jackets and 
secure bandage. 
 
Increase tensile forces 
around the wound site, 
may counteract fibrosis 
and scarring. 
 
Distraction device [365] 
(Screw-driven retractor with teeth 
projecting into the wound margin 






Wound chamber [366] 
(A pair of metal rings clamped 
together to enclose a skin fold in 
which one side of the fold includes a 
full-thickness excisional wound that 
has a transparent glass or plastic 
window.) 








and upset angiogenic 











3.3.3 Creating a moist wound healing environment with topical 
gel  
 
In Hypothesis 3, I sought to create a moist wound healing environment which is 
a standard of care for chronic wound treatment [272]. A moist wound healing 
environment is more likely to promote wound healing and autolytic debridment 
as compared to a dry environment [272]. Here I prepared a topical aqueous-
based gel treatment using sodium carboxymethylcellulose, a natural cellulose 
derivative that is widely used in FDA-approved wound healing gels such as 
becalpermin [273]. The treatment gel contained 2% w/v sodium 
carboxymethylcellulose (Aquasorb A-500, Ashland, KY), 4 mg/ml fatty acid free 
rat serum albumin, 1% dimethyl sulfoxide with 0.1 mM CPX and 0.01 mM S1P. 
The placebo/control gel treatment excluded CPX and S1P. To remove air 
bubbles, both gel types were centrifuged under vacuum for 5 minutes. 
 
3.3.4 Creating a full-thickness excisional wound  
 
15 eight-week old female obese Zucker diabetic fatty (ZDF) rats (Charles River 
Laboratories, Boston, MA) were randomly divided into three groups: (1) 
nondiabetic ZDF rats treated with control gel, (2) diabetic ZDF rats treated with 
control gel, and (3) diabetic ZDF rats treated with CPX+S1P gel. Nondiabetic 
rats were maintained on standard laboratory chow while diabetic rat groups 
were fed with a 48% kcal high fat diet (D12468, Research Diets Inc., NJ) ad 
libitum to induce diabetes. Rats were considered diabetic when non-fasting 





Pre-surgery procedures were done in a laminar flowhood (Figure 3.2). Rats 18- 
to 20-weeks old were anesthetized with inhalant isoflurane (1.5%) with 2 litres 
per minute of oxygen and placed over a heating pad. Ophthalmic ointment was 
applied. Analgesic (meloxicam: 4 mg/kg), antibiotics (enrofloxacin 5mg/kg) and 
4 ml of saline were subcutaneously injected. The dorsal fur was shaved (Oster 
Golden A5 Clipper; size 50 blade) and treated with a depilatory cream (90 
seconds; Veet, Reckitt Benckiser, Slough, United Kingdom) to remove 
remaining fur. Remnants of the depilatory cream were removed with a wet 
gauze. The dorsum of the rats was disinfected with 70% ethanol. 
 
 




Surgical procedure: Wound depth increment  
 
The surgical procedures were performed in a biosafety cabinet (Figure 3.3), 
located in proximity to a surgical side table (Figure 3.4). Rats were laid on a 
heating pad and continued to receive inhalant isoflurane (1.5%) with 2 litres per 
minute of oxygen. A sterile drape (Halyard Health, Alpharetta, GA) was overlaid 
on the dorsum of the rat. The dorsum of the rat was disinfected with povidone-
iodine and 70% ethanol.  
 
  




Figure 3.4 Surgery side table.  
 
A sterile template (designed from an autoclave bag) was overlaid on the dorsum 
and 2 square wound sites measuring 15 mm x 15 mm, located 2.5 cm caudal to 
the shoulder blades and 3cm apart, were marked out with a sterile skin marker 
(Figure 3.5A). 
 
To create a superficial wound of approximately 1 mm depth, an iris 
dissecting forcep (B.Braun, Melsungen, Germany) was used to lift the skin away 
the underlying fat pad. Thereafter a ligature curved scissor (B.Braun) was used 
to excise the full-thickness skin along the confines of the wound site (Figure 
3.5B, 3.5D). Metzenbaum scissors aided in separating the skin from the 




To create a deep wound of approximately 3 mm, first create a superficial 
wound and then using a forcep, gently lift up the underlying fat pad and excise 
it with a ligature curved scissors along the confines of the square wound. The 
deep fascia and skeletal muscles can be clearly seen after excision. Note that 
contralateral wounds on the same rat were excised to the the same depth. Also 
during excision, isoflurane was increased to 3%. 
 
Surgical procedure: Splinting 
 
Superglue (Liquid; Scotch, 3M, St. Paul, MNA) was applied onto a silicone splint 
(internal diameter: 15 mm by 1.5 mm, Grace Bio-Labs, Bend, OR) and centred 
on the wound. (Figure 3.5E, 3.5F). Using a sterile gauze, the splint was gently 
pressed down (~30 seconds) on the perilesional skin for adherence. The splint 
was fastened to the edges of the wound with 16 interrupted sutures (Premilene 
polypropylene monofilament non-absorbable 5/0 cutting suture, B.Braun), in a 
progression as indicated in Figure 3.5G. As the sutures were inserted through 
the skin, the isoflurane was increased to 3%, and when it was pulled through 





Figure 3.5 Surgical procedures. 
 
This variation in isoflurane levels and high oxygen levels was found to be crucial 
for the survival of ZDF rats. An initial maintenance on 2% isoflurane and 1.5 litre 
per minute of oxygen throughout the surgery led to an overdosing of isoflurane 
in the obese ZDF rats. This is likely attributed to the high absorption of isoflurane 
in adipose tissue [274]. Such complication was not reported by previous groups 
using obese ZDF in wound healing studies [20,275], perhaps due to the much 









Post-Surgical procedures were performed in a laminar flowhood (Figure 3.6). A 
non‑adherent dressing (Guardian, Singapore) was overlaid onto the wound site 
and held temporarily in place by forceps (Figure 3.7A). Thereafter Opsite was 
sprayed on the dorsal region and an Opsite Flexifix dressing (Smith & Nephew, 
London, United Kingdom) was overlaid (Figure 3.7B). Next, a Coban bandage 
(3M) was placed over the dressing and affixed to the skin with adhesive tapes 
(Figure 3.7C). Analgesic (meloxicam: 4mg/kg), antibiotics (enrofloxacin 5mg/kg) 
were given 7-days post-op. 24 hours after surgery, contralateral wounds on the 
same rat were treated with the same drug i.e. either 0.5 ml CPX+S1P gel or 0.5 
ml control gel. A treatment delay of 24 hours was elected to test the translational 
robustness of CPX+S1P under clinical setting where diabetics are commonly 
plagued with peripheral neuropathy [367] leading to a loss of cutaneous 
sensation and a delay in wound treatment. In this experiment, the drug 
treatments were continued every alternate day at which occasion wounds were 




Figure 3.6 Wound dressing setup in a laminar flow hood.  
 
 





Wound area measurement 
 
Wound area was measured using ImageJ software calibrated against the 
internal length of the splint. From the macroscopic images, the margin of 
advancing epithelium was traced and the area within the margin of advancing 
epithelium was defined as wound area. Wound size reduction was expressed 
as % 𝑤𝑜𝑢𝑛𝑑 𝑎𝑟𝑒𝑎 =
𝑤𝑜𝑢𝑛𝑑 𝑎𝑟𝑒𝑎 𝑜𝑛 𝐷𝑎𝑦 𝑛
𝑤𝑜𝑢𝑛𝑑 𝑎𝑟𝑒𝑎 𝑜𝑛 𝐷𝑎𝑦 1
 × 100 . Rats were sacrificed a month 
post-surgery. As contraction was macroscopically observed to occur in major 
direction i.e. away from the spine ( Figure 3.8 ), the wounds were bisected along 
the main direction of contraction. Excised wounds were next fixed in formalin 
overnight prior to paraffin embedding. All animal experiments were reviewed 
and approved by the Institutional Animal Care and Use Committee of the 
Biomedical Research Committee (BRC IACUC, protocol number 140929). 
 
Figure 3.8 Schematics of contralateral wounds on the rat dorsum. Wounds 
indicated by the square) are bisected along the major direction of contraction i.e. 








8 µm paraffin sections from the center of the wound, cut perpendicularly to the 
wound surface, were stained using standard protocols for hematoxylin and 
eosin (H&E), Masson’s trichrome blue and Picrosirius red. Brightfield images 
were taken at 20x magnification with an Olympus IX31 microscope (Tokyo, 
Japan). Antigen retrieval was done at 100oC in BondTM  Epitope Retrieval 
Solution (Leica, Nußloch, Germany) at pH 9 for 40 minutes. Endogenous 
peroxidase activity was blocked for 15 minutes in 3% (v/v) hydrogen peroxide 
and sections were then rinsed 5 times in BondTM Wash solution (Leica). 
Sections were blocked in 10% goat serum for 30 minutes prior to incubation with 
rabbit monoclonal antibodies to alpha-smooth muscle actin (α-SMA) (1:1000 
dilution, 2 hours, Abcam), matrix metalloproteinase (MMP)-3 (1:100 dilution, 15 
minutes, Abcam); rabbit polyclonal MMP-13 (1:100 dilution, 15minutes, Abcam); 
mouse monoclonal antibodies to RECA-1 (1:50 dilution for 16hours) and Ki-67 
(1:50 dilution for 15 minutes, Dako, Agilent). BondTM Refine Detection Kit 
(Leica)– polymer reagent was used to detect the primary antibody and the 
sections were stained with 3,3'-diaminobenzidine (DAB) as a chromogen and 
lightly counterstained with Mayer’s hematoxylin. Apoptosis was assesed using 
a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 
(Merck Milipore, Danvers, MA, USA). Brightfield images were captured at 20x 





3.3.6 Morphometric analysis of immunostained areas 
 
Using ImageJ software immunohistochemical images were first white balanced 
and deconvoluted into their indiviual components using the Colour devolution 
plugin [276]. The 3,3'-diaminobenzidine images were converted into an 8-bit 
image and auto-thresholded to measure percentage area.  
 
3.3.7 Quantification of function vessel density 
 
RECA-1 positive vessels (with lumina containing red blood cells) were counted 
under a 20x magnification field of view in 6-8 randomly chosen optical fields on 
2 adjacent sections (200 µm apart) per wound. The mean cross-sectional area 
of functional vessels was measured as the area of RECA-1 positive 
immunofluoresence including the lumen it surrounds. This area was measured 
using the ROI plugin from ImageJ software.  
 
3.3.8 Evaluation of collagen fiber thickness  
 
Collagen fiber thickness was assessed semiquantitatively by Picrosirius red 
staining viewed under linear polarized light under which thin collagen fibers 
appear green to greenish yellow, while thick fibers appear orange to red. To 
determine the proportion of thin to thick collagen fibers, we resolved the 
polarized Picrosirius red subtracted image into hue components using the colour 
threshold plugin in ImageJ. We used the following hue definitions; green to 
yellow 0-22, and orange to red 22-255. Images from each hue range were 
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converted to 8-bit hue images and thresholded and the percentage of collagen 
fibers in each hue per total number of collagen pixels in the image was 
determined.  
 
3.3.9 MMP in vitro activity assay  
 
Human MMP-3 and MMP-13 full length protein (Abcam) were activated using 4-
Aminophenylmercuric Acetate (APMA) according to the manufacturer’s protocol 
(MMP activity assay kit ab112147, Abcam). 30 ng of APMA-activated MMP-3 
and MMP-13 were mixed with CPX (0 to 100 µM) for 15 min prior to exposure 
to the MMP red fluorescence resonance energy transfer peptide substrate. As 
a negative control, APMA-activated MMP-3 was mixed with MMP-3 Inhibitor V 
(300 ng /100 ul) (Santa Cruz Biotechnology, Santa Cruz, CA) while APMA-
activated MMP-13 was mixed with its inhibitor CL82198 hydrochloride 
(300ng/100ul) (Tocris, Bristol, United Kingdom). Fluorescence signal was 
captured after one hour using a Tecan microplate reader (Männedorf, 
Switzerland) with a filter set of Ex/Em = 540/595 nm 
 
3.4 Statistical Analysis 
 
All in vitro and in vivo work was performed in replicates of 2 to 8 as indicated in 
the figure legends. Statistical significance was determined by Student’s t-test 
distribution. Differences were considered statistically significant when p < 0.05. 

















4.1 Hypothesis 1: 
CPX+S1P potentiates HIF-1 activity in vitro 
 
4.1.1 CPX+S1P potentiates HIF-1α expression  
 
The first Hypothesis in this study was to ascertain whether the combination 
CPX+S1P potentiates HIF-1 activity in endothelial cells (Methods § 3.1), and 
this proved to be the case. As HIF-1α stability is a crucial determinant of HIF-1 
activity, I identified 5 hours 30 minutes as the optimal time point to detect HIF-
1α protein stabilization in HUVECs (hereinafter rounded off to 6 hours for ease 
of display and reading). During an 8-hour follow-up after 10 μM CPX stimulation, 
appreciable amounts of HIF-1α protein started to accumulate one hour post- 
stimulation and attained a maximum at around 6 hours (Figure 4.1A). S1P also 
induced HIF-1α protein stabilization with similar kinetics (Figure 4.1B).  
 
My lab previously demonstrated that ~10 μM CPX is highly effective in 
promoting HUVEC sprouting [21]. Accordingly, I identified 10 μM CPX and 0.25 
µM S1P as optimal concentrations to increase HIF-1α protein levels in vitro. 
10µM CPX effectively increases HIF-1α protein levels, with maximum stability 
beyond 20 µM (Figure 4.2A); however, I chose to use 10 µM for further studies, 
as higher CPX concentrations can completely cross-inhibit deoxyhypusine 
hydroxylase in HUVECs, resulting in an inhibition of DNA synthesis and 
proliferation which are crucial for sprouting [277]. S1P maximally increased HIF-
1α protein levels after 6 hours without dose-dependency in the range of 0.125 
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μM to 1 μM (Figure 4.2B). At 6 hours, the combination of 10 µM CPX + 0.25 µM 
S1P increased HIF-1α expression levels by 14.0-fold compared to the untreated 
control, while CPX alone increased it by 10.7-fold and S1P increased it by 1.4-
fold (Figure 4.3A). This HIF-1α induction by CPX+S1P exceeded ithe induction 
power of its individual components ( 14.0-fold > (10.7+1.4)-fold ). 
 
 
Figure 4.1. Representative western blots of HIF-1α protein and β-actin protein 
expression in HUVECS after treatment with: (A) 10 μM Ciclopirox Olamine 
(CPX) over time course of 8 hours; (B) 0.25 μM Sphingosine-1-Phosphate (S1P) 
over a time course of 6 hours. No quantitative assessment was made for these 





Figure 4.2. Representative western blots of HIF-1α protein and β-actin protein 
expression in HUVECS after treatment with: (A) 1 μM to 40μM CPX after 6hours 
and (B) 0.125 μM to 2 μM S1P after 6 hours. No quantitative assessment was 






Figure 4.3. Representative western blots of HIF-1α protein and β-actin protein 
expression after 6 hours in HUVECS treated with individual or combination of 
0.25 µM S1P and 10 µM CPX. Quantitative assessment represented in the bar 
graph is derived from n = 3 replicate experiments. Error bars represent standard 
error. Each replicate experiment is a singular treatment. CPX+S1P increases 
HIF-1α protein levels in a manner that exceeds its additive effect. Significance 









4.1.2 CPX+S1P potentiates p42/44 MAPK activity 
 
I determined the activation of p42/44 MAPK by assessing its phosphorylated 
protein levels (Methods § 3.1). The activation of p42/44 MAPK promotes the 
transactivation of HIF-1 complex and thus is another positive regulator of HIF-1 
activity [243,244]. Compared to the untreated control, 10 µM CPX inhibited 
phosphorylation of p42/44 MAPK by 0.4-fold while S1P slightly stimulated it by 
0.2–fold (Figure 4.4). Interestingly, the addition of 0.25 µM S1P not only 
reversed CPX’s inhibition but also increased the phosphorylation of p42/44 






Figure 4.4. Representative western blots of phosphorylated p42/44 MAPK 
protein and β-actin protein expression after 6 hours in HUVECS treated with 
individual or combination of 0.25 µM S1P and 10 µM CPX. Quantitative 
assessment represented in the bar graph is derived from n = 3 or 5 replicate 
treatments from duplicate experiments. Error bars represent standard error. 
CPX+S1P increases phosphorylated p42/44 MAPK protein levels in a manner 
that not only exceeds its additive effect but reverses CPX-induced inhibition. 









4.1.3 CPX+S1P potentiates HIF-1 downstream activity 
 
Having established that CPX+S1P increases two crucial upstream regulators of 
HIF-1 activity i.e., HIF-1α protein levels and Phosphorylated p42/44MAPK 
protein levels, I evaluated the protein expression of three HIF-1 downstream 
angiogenic targets (VEGF, c-MET and eNOS) in the HUVEC monolayer upon 
treatment with CPX, S1P or its combination (Figure 4.5 to 4.7).  
 
10 µM CPX + 0.25 µM S1P caused an upregulation of all three HIF-1 targets in 
an additive manner. In the first downstream angiogenic target – VEGF, 
treatment with CPX alone increased its protein level by 1.1-fold compared to the 
untreated control while treatment with S1P alone increased it by 0.4-fold. And 
under their combinatory treatment, VEGF protein levels additively increased by 
~ 1.7-fold. In the second downstream angiogenic target – c-MET, treatment with 
CPX alone induced a 1.6-fold increase in c-MET protein levels compared to the 
untreated control while treatment with S1P alone induced a 0.7-fold increase. 
Under their combinatory treatment, c-MET protein levels additively increased by 
~2.4-fold. In the third downstream angiogenic target – eNOS, treatment with 
CPX alone increased eNOS protein levels by 1.0-fold compared to the untreated 
control while treatment with S1P alone increased it by 0.3-fold. Once again their 












Figure 4.5. Representative western blots of VEGF protein and β-actin protein 
expression after 6 hours in HUVECS treated with individual or combination of 
0.25 µM S1P and 10 µM CPX. Quantitative assessment represented in the bar 
graph is derived from n = 4 replicate treatments from a single experiment. Error 
bars represent standard error. CPX+S1P increases VEGF protein level in an 









Figure 4.6. Representative western blots of c-MET protein and β-actin protein 
expression after 6 hours in HUVECS treated with individual or combination of 
0.25 µM S1P and 10 µM CPX. Quantitative assessment represented in the bar 
graph is derived from n = 3 replicate treatments from singular experiment. Error 
bars represent standard error. CPX+S1P increases c-MET protein level in an 









Figure 4.7. Representative western blots of eNOS protein and β-actin protein 
expression after 6 hours in HUVECS treated with individual or combination of 
0.25 µM S1P and 10 µM CPX. Quantitative assessment represented in the bar 
graph is derived from n = 3 replicate treatments from singular experiment. Error 
bars represent standard error. CPX+S1P increases eNOS protein level in an 




4.2 Hypothesis 2: 
CPX+S1P potentiates angiogenesis in vivo 
 
The second Hypothesis in this study was to ascertain whether the combination 
CPX+S1P potentiates functional vessel formation in subcutaneously implanted 
sponges (Figure 4.8A; Methods § 3.2), and this proved to be the case. Here 
CPX (0.01 mM to 1 mM) and S1P (0.001 mM to 0.1 mM) were titrated to identify 
a concentration that would maximally induce endothelial cell (EC) infiltration into 
the sponge. Surprisingly, the entire range of CPX concentrations proved 
effective in inducing EC infiltration (Figure 4.8B) without evident dose-
dependency in the concentration range chosen. Similarly, the entire range of 
S1P concentrations tested induced EC infiltration, without evidence for a 
superior dose (Figure 4.8B). For this in vivo study, I chose a concentration of 
0.1 mM CPX and 0.01 mM S1P. This combination potentiated EC infiltration in 
a manner that exceeds their additive effect (Figure 4.9). Compared to the 
vehicle treatment, CPX alone increases EC infiltration by 1.5-fold, S1P alone by 
1.1-fold and its combination increases EC infiltration by 3.6-fold (> 2.6-fold 
additive effect). Moreover, I noted the formation of long contiguous EC 
structures under CPX+S1P treatment, suggesting functional vessel formation 
(Figure 4.9, white arrows). Indeed, FITC-isolectin data revealed non-leaky 
perfusion of these structures, demonstrating potentiation of functional vessel 






Figure 4.8. (A) Representative image of a PVA sponge explant that was 
subcutaneously implanted in the dorsum of a Sprague dawley rat for 3 weeks. 
Macroscopic observation shows granulation tissue infiltration into the centre of 
the sponge. (B) Quantitative assessment of EC infiltration into PVA sponge 
titrated under CPX: 0.01 mM, 0.1 mM, 1 mM and S1P: 0.001 mM, 0.01 mM and 
0.1 mM. Entire titrated range of CPX, S1P induced EC infiltration. Error bars 
represent standard deviation. Significance * p < 0.05 is derived from Student’s 
two-tailed t-test. n = replicate treatments in the same animal. #: Reason for n < 
4: Sponges explants from sites where rats inflicted additional wounding were 





Figure 4.9. EC infiltration into subcutaneously implanted PVA sponges, 
identified by RECA-1 immunofluoresence (red), was potentiated under the 
combination of CPX 0.01 mM and S1P 0.01 mM in a manner that exceeds its 
additive effect. Cell nuclei identified by DAPI (blue). White arrows indicate 
contiguous structures of endothelial cells. Error bars represent standard 
deviation. Significance * p < 0.05 is derived from Student’s two-tailed t-test. n = 
replicate treatments in the same animal. #: Reason for n < 4: Sponges explants 










Figure 4.10. Combination of CPX 0.01 mM and S1P 0.01 mM potentiated FITC-
isolectin perfused vessel length in a manner that exceeds its additive effect. 
Images represent 40x magnification of 2D images of vessels projected from 3D 
confocal stack. Cell nuclei identified by DAPI (blue), EC identified by RECA-1 
(red) and functional vessels identified by perfused FITC-isolectin (green). FITC-
isolectin vessel length measured using ImageJ plugin – Analyze Skeleton. 
Vessel length quantified from 5 to 8 random sites in each treatment condition. 
Error bars represent standard error. Significance * p < 0.05 is derived from 








4.3 Hypothesis 3: 
CPX+S1P increases diabetic wound contraction 
 
The third Hypothesis in this study was to ascertain whether the combination 
CPX+S1P potentiates full-thickness wound contraction in diabetic female ZDF 
rats. More specifically, I assessed contraction at two wound depths i.e., 1 mm 
(superficial) and 3 mm (deep) (Methods §3.3.4). CPX+S1P increased 
contraction in deep but not superficial wounds a month post-wounding.  
 
4.3.1 Severe diabetes successfully induced in female ZDF rats 
 
The experiment began by inducing diabetes in female ZDF rats with a high fat 
diet. Overt hyperglycemia was seen after 4 weeks of a high fat diet where by 
non-fasting plasma glucose levels reached 550 mmol/dl (30 mg/L), a threefold 
increase compared to when maintained on a standard diet (Figure 4.11, 
Methods § 3.3.4). This hyperglycaemic condition was successfully maintained 
throughout the course of the experiment. Both nondiabetic and diabetic rats did 
not display significant differences in weight (Figure 4.11). From 12 weeks of 
age, the diabetic rats displayed typical hallmark traits of severe diabetes. They 
exhibited polyuria, urinary tract infection, pressure ulcers and dry skin (Figure 
4.12A-C). They also developed fatty liver with hepatocytes containing 
glycogenated nuclei (glycogen vacuolations of the nuclei) (Figure 4.12D-E). The 
glomerulus capsular space in the kidney cortex of diabetic rats were also 
observed to be obliterated with hyaline. A loss of distal tubules were also 
102 
 
observed in the interstitial regions of the kidney cortex and were accompanied 
by the infiltration of inflammatory cells, a hallmark of glomerulonephritis (Figure 
4.12 F-G). These effects were not observed in nondiabetic rats.  
 
Table 6 shows (i) intended number of wounds for the different treatment 
conditions, (ii) the number of wounds lost (due to serious diabetic complications, 
isoflurane overdosing, wound infection and splints bitten off by rats) and (iii) the 











Figure 4.11 Changes in mass (top panel) and non-fasting plasma glucose levels 
(bottom panel) of female ZDF rats maintained on a standard diet (black line) or 
a 40% lard high fat diet (red line) from 8-week old for a period of 16 weeks. 
Increase in plasma glucose levels were observed in ZDF rats maintained on a 
high fat diet after 2 weeks. Significance * p < 0.05 is derived from Student’s two-
tailed t-test. Error bars represent standard error. n = number of rats. For 
convenience, only changes in n numbers are stated and specified in bottom 
panel. n values for the top and bottom panels are the same. Wound healing 
study was conducted when ZDF rats were 18 to 24-week old.  The drop in rat 
numbers at the onset of the wound healing experiment is due to isoflurane 




Figure. 4.12 Complications of diabetes in ZDF female rats after 16 weeks of 
high fat diet. Diabetic rats exhibited (A) pressure ulcers in their lower abdomen 
(arrowhead), (B) urinary tract infection with observable pus in their urethra 
(arrow), (C) necrotic tail (rat died prior to surgery). (D,E) H&E stained liver cross-
section from diabetic female ZDF rat reveals glycogenated hepatocyte nuclei 
around the central vein (arrowhead) and fatty deposits (arrow). (F,G) H&E 
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stained kidney cortex cross-section from nondiabetic and diabetic rat. 
Glomerulus is traced with dotted line. *Hyaline is observed to obliterate capsular 
space in the glomerulus of diabetic ZDF rats. Inflammatory interstitial infiltration 
(arrowhead), and loss of distal tubules were were also observed in the diabetic 
ZDF rat. These effects were not observed in kidney cortex of nondiabetic ZDF 
rat. 
 
Table 6. Treatment conditions in the 4-week full-thickness skin wound model. 
 
4.3.2 Identification of dorsal sites for wound depth variation  
 
I identified dorsal wound sites cranial to the transverse plane as choice sites for 
excision (Figure 4.13A). These sites possess a fat pad that allows for wound 
depth variation (Figure 4.13B; Methods § 3.3.4 ) that is absent in dorsal regions 
caudal to the transverse plane (Figure 4.13B and 4.13D). I therefore could 
create a superficial, yet full-thickness wound of ~1 mm depth by excising skin 
through the panniculus carnosus down to the superficial fascial layer (Figure 
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4.13C; short vertical arrow) or a deep (~3 mm depth) wound reaching down to 
the deep fascial layer (Figure 4.13C; long vertical arrow).  
 
 
Figure 4.13. Full-thickness wound excisional model. (A) Two 1.5 cm by 1.5 cm 
full thickness skin wound were excised in the dorsal wound sites of female ZDF 
rats located 2.5 cm from the shoulder blade and 3 cm apart. Silicone splints 
were superglued to perilesional skin and sutured to the wound edges. (B) Full 
thickness skin incision along the dorsal midline of the ZDF female rat reveals a 
fat pad (*) located cranially but not caudally to the transverse plane. H&E stained 
section of skin excised down to the skeletal muscles from regions located 
cranially (C), and caudally (D) to the transverse plane. Vertical arrows represent 
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the two depths of skin excision used in this study. Superficial wounds are 
excised through the panniculus carnosus down to the superficial fascial. Deep 
wounds are excised down to the deep fascial layer. Asterisk in (C) (*) 
corresponds to the fat pad seen macroscopically in (B). 
 
 
4.3.3 Differential effects of CPX+S1P on wound closure at 
different wound depths 
 
Wound closure was macroscopically analysed through the disappearance of 
light-reflecting new stroma and the replacement of a non-reflecting fully 
epithelialized surface (Figure 4.14; Methods § 3.3.4). 0.1 mM CPX + 0.01 mM 
S1P treatment was found to promote significant diabetic wound closure in deep 
wounds (Figure 4.14). On day 8, macroscopic images of deep wounds revealed 
a migration of the mobile perilesional adipose layer into the wound cavity. 
CPX+S1P treated deep diabetic wounds showed a strikingly redder perilesional 
adipose layer than control wounds, suggesting an increased vascularization and 
perfusion. By day 16, CPX+S1P reduced deep diabetic wound-size from 93% 
to 77% (Figure 4.14) and on day 18 the reduction was found to be significant (* 
p < 0.05). By day 31, CPX+S1P treated deep diabetic wounds were reduced to 
27% of the original wound size while the control group was at 42%. Interestingly, 
CPX+S1P treatment did not significantly increase wound closure in superficial 
diabetic wounds, although it increased normalization of wound closure towards 







Figure 4.14 Representative macroscopic wound closure images in full-
thickness deep diabetic ZDF rat wounds. Wounds were topically treated with or 
without 0.1 mM CPX + 0.01 mM S1P every other day starting from day 2. A 
millimetre rule was place beneath each wound when imaged. Graph of 
macroscopic wound area measured as a percentage of initial wound area 
reveals a significant increase in CPX+S1P treated deep wound closure on day 
18. Wound area was identified as the area within the margin of the leading edge 
of advancing epithelium and measured using ImageJ software calibrated 
against the internal length of the splint. Significance * p < 0.05 is derived from 
Student’s two-tailed t-test. Error bars represent standard error. Day 1 to 7: n = 
6 wound replicate treatments. Day 8 onwards: n = 2 wound replicate treatments 




Figure 4.15 Representative macroscopic wound closure images in full-
thickness superficial diabetic ZDF rat wounds. Wounds were topically treated 
with or without 0.1 mM CPX + 0.01 mM S1P every other day starting from day 
2. A millimetre rule was place beneath each wound when imaged. Graph of 
macroscopic wound area measured as a percentage of initial wound area 
reveals a significant increase in nondiabetic superficial wound closure by day 
26. Wound area was identified as the area within the margin of the leading edge 
of advancing epithelium and measured using ImageJ software calibrated 
against the internal length of the splint. Significance * p < 0.05 (non-diabetic 
compared against diabetic) is derived from Student’s two-tailed t-test. Error bars 
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represent standard error. Day 1 to 7: n = 8 diabetic wound replicate treatments 
and n = 2 nondiabetic wound replicate treatments from same rat. Day 8 
onwards: n = 4 diabetic wound replicate treatments, n = 2 nondiabetic wound 
replicate treatments from the same rat. The drop in n numbers is explained in 
Table 6. 
 
4.3.4 Effects of CPX+S1P on wound contraction at different 
wound depths 
 
To better understand the relationship between wound depth and wound closure, 
I measured the contribution of contraction and re-epithelialization to wound 
closure from H&E stained sections (Methods § 3.3.5) and expressed them as a 
percentage of the original wound length (Figure 4.16).  
 
Re-epithelialization (indicated by the single headed arrow) was measured as 
the length of keratinocytes extending beyond the end of the unwounded dermis. 
Wound gap (indicated by the double headed arrow) was measured as the length 
between the tip of the new epithelial tongue. Contraction was measured with the 
formula: 
% 𝐶𝑜𝑛𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =
 𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑤𝑜𝑢𝑛𝑑 𝑙𝑒𝑛𝑔𝑡ℎ−(𝑛𝑒𝑤 𝑒𝑝𝑖𝑡ℎ𝑒𝑙𝑖𝑎𝑙 𝑡𝑜𝑛𝑔𝑢𝑒 𝑙𝑒𝑛𝑔𝑡ℎ+𝑤𝑜𝑢𝑛𝑑 𝑔𝑎𝑝) 
𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑤𝑜𝑢𝑛𝑑 𝑙𝑒𝑛𝑔𝑡ℎ
× 100  
 
Even under splinting, superficial diabetic wounds contracted by 51%, and 
effects of CPX+S1P remained inconspicuous. In contrast, splinted deep diabetic 
wounds contracted only by 8%, and here CPX+S1P significantly (** p < 0.01) 
rescued contraction from 8% to 39%. At both wound depths, CPX+S1P did not 





Figure 4.16 Representative haematoxylin and esosin stained full-thickness 
deep wounds (rows 1 and 2) and full-thickness superficial wounds (rows 3 to 5), 
a month post-wounding. Graph on the right represents the contribution of wound 
closure mechanisms: contraction and re-epithelialization. Black area represents 
contraction, grey area represents re-epithelialization (E) and white area the 
wound gap (W). These parameters are assessed from H&E stained tissue 
sections and expressed as a percentage of the original wound length. Re-
epithelialization (indicated by E and single headed arrow) is measured as the 
length of keratinocytes extending beyond the end of the unwounded dermis 
(indicated by D). Wound gap (indicated by the W and double headed arrow) is 
measured as the length between the tip of the new epithelial tongue. 
Granulation tissue is indicated by G.T. Contraction is measured as the 
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difference between the original wound length and the sum of (wound gap + re-
epithelialized length). Contraction was found to be significantly attenuated with 
an increase in wound depth, while a supplementation of 0.1mM CPX + 0.01mM 
S1P rescued wound contraction in in deep diabetic wounds. Significance * p  < 
0.05, ** p < 0.01 is derived from Student’s two-tailed t-test. Error bars represent 
standard deviation. n = 4 superficial diabetic wound replicates and n = 2 deep 
diabetic & superficial nondiabetic wound replicates from the same rat. Note: The 
absence of the deep nondiabetic wound control is explained in Table 6.  
 
4.3.5 CPX+S1P enhances granulation tissue in deep diabetic 
wounds 
 
As wound contraction in humans depends on granulation tissue deposition and 
compaction, I evaluated the effects of CPX+S1P on collagen deposition in deep 
diabetic wounds (Methods § 3.3.5). Masson’s trichrome blue staining of 
CPX+S1P-treated deep diabetic wounds suggested a collagen rich granulation 
matrix (Figure 4.17) while the control diabetic group appeared predominantly in 
red in the Masson trichrome stain, suggesting a cell-rich and collagen-poor 
granulation tissue (Figure 4.17). In addition, CPX+S1P treatment appeared to 
induce more proliferation and less apoptosis in the cellular component of the 
granulation tissue (Figure 4.18; Methods § 3.3.5). 
 
These data were confirmed semiquantitatively with Picrosirius red staining 
(Figure 4.19; Methods § 3.3.8). Here sirius red dye binds to collagen, promoting 
the enhancement of its normal birefringence when the dye molecules are 
aligned parallel with the long axis of the each collagen molecule. When viewed 
under polarized light, the color and intensity of birefringence is a result of 
differences in the pattern of physical aggregation and thickness of collagen 
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fibres [278]. Thus thin and poorly packed collagen fibres appear green to 
greenish yellow polarizing colours, while thick and tightly packed fibres exhibit 
orange to red polarizing colours. CPX+S1P treatment significantly (*p < 0.01) 
increased the proportion of thick and tightly-packed collagen fibres from 42% to 
85%, while decreasing thin and poorly packed collagen fibres from 58% to 15% 










Figure 4.17 A) Representative Masson trichrome blue stained wound sections 
of full-thickness deep diabetic wounds 31 days post-treatment with or without 
0.1 mM CPX + 0.01 mM S1P. Dotted lines indicate granulation tissue region. 
Qualitatively, CPX+S1P observed to increase collagen (blue stain) within the 
granulation tissue region. B) Quantitative assessment of collagen area derived 
from polarized picrosirus red stained sections of granulation tissue. The total 
area of polarized picrosirus red stain from 20x magnification images was 
thresholded using ImageJ. Significance * p < 0.05, is derived from Student’s 
two-tailed t-test. Error bars represent standard deviation. n = 2 replicates 




Figure 4.18 Representative images of proliferation and apoptosis in granulation 
tissue of full-thickness deep diabetic wounds 31 days post-treatment with or 
without 0.1 mM CPX + 0.01 mM S1P. (A) CPX+S1P appeared to increase 
proliferating cells (Ki-67 brown stain) and (B) decrease apoptotic cells (TUNEL 
brown stain; red arrowhead). Cell nuclei counterstained with hematoxylin. 
Quantification was done on 4 high powered 20x magnification field in each 
replicate. Quantification done at 20x magnification field. Increase is not 
significant as determined by Student’s two-tailed t-test * p < 0.05. Error bars 





Figure 4.19 Ratio of thick versus thin collagen fibers in full-thickness deep 
diabetic wounds 31 days post-treatment with or without 0.1 mM CPX + 0.01 mM 
S1P. Representative images of picrosirius red stained collagen fibers (red). 
Inset i-iv corresponds to the Picrosirius red images viewed under linearly 
polarised light at 64x magnification. Here thin and poorly packed collagen fibers 
exhibit green to yellow polarizing colors, while thick and tightly packed fibers 
exhibit orange to red polarizing colors. Area of collagen fiber hue measured 
using ImageJ’s colour threshold plugin. Quantification done at 40x magnification 
field. Significance * p < 0.05, is derived from Student’s t-test. Error bars 
represent standard error. n = 2 replicates form the same rat. Graph reveals that 
CPX+S1P treatment significantly increases the proportion of orange to red 
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collagen fiber hue and decreased the proportion of green to yellow collagen fiber 
hue.  
 
4.3.6 CPX+S1P promotes large vessel formation 
 
In addition to an increase in collagen deposition and compaction, I observed a 
concurrent increase in angiogenesis in CPX+S1P treated deep diabetic wounds 
signified by a 1.8-fold increased in EC infiltration (Figure 4.20A, Methods 
§3.3.7). However, the total vessel density did not increase but the mean cross-
sectional area of functional vessels rose from 300 µm2 to 860 µm2. Segregation 
of vessel-sizes according to their cross-sectional area into small (<200 µm2), 
medium (between 200 µm2 to 1000 µm2) and large vessels (>1000 µm2) 
revealed a significant (*p < 0.05) increase in large vessel density under 
CPX+S1P (Figure 4.20B). Histologically, these large vessels appeared 
















Figure 4.20. Angiogenesis in granulation tissue of full-thickness deep diabetic 
wounds with or without 0.1mM CPX + 0.01mM S1P treatment 31 days post-
wounding. (A) Representative Immunohistochemical localization of RECA-1 
positive endothelial cells (brown). Nuclei counterstained with haematoxylin 
(blue). Area quantification was done on 6 20x magnification field in each 
replicate.Graph of RECA-1 positive area reveals a significant increase in 
endothelial cell infiltration with CPX+S1P. (B) Graph of vessel density of small 
vessels (cross-sectional area <200 µm2), medium vessels (cross-sectional area 
between 200 µm2 and 1000 µm2) and large vessels (cross-sectional area >1000 
µm2) induced with or without CPX+S1P treatment. Functional vessels i.e., 
RECA-1 positive lumina containing red blood cells, are represented by solid 
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areas. Vessel density quantified from 23 random sites in each treatment 
condition. Significance * p < 0.05, is derived from Student’s t-test. Error bars 
represent standard error. n = 2 wound replicate from the same rat. 
 
 
4.3.7 CPX+S1P reduces α-SMA expression in granulation 
tissue 
 
 An increased presence of myofibroblasts is associated with increased wound 
contraction. Using α-SMA antibody as marker we found an intense and even 
distribution of myofibroblasts in the deep diabetic wounds of the control group 
(Figure 4.21; Methods §3.3.5). At a higher magnification, α-SMA expression 
was seen to be located specifically at cell to cell junctions forming a cobble-
stone like morphology in the upper-half of the granulation tissue (Figure 4.21, 
inset i); and in the lower-half adopting a typical myofibroblastic morphology 
(Figure 4.21, inset ii). Interestingly, under CPX+S1P treatment, α-SMA 
expression was only intense in the upper-half of the granulation matrix with a 
~40% decrease in the lower-half of the matrix. α-SMA expression was also 
observed in spindle-like cells (Figure 4.21, inset iii), but primarily in mature blood 











Figure 4.21 Representative Immunohistochemical localization of α-SMA 
expression (brown) in granulation tissue of deep diabetic full-thickness wounds 
with or without 0.1mM CPX + 0.01mM S1P treatment 31 days post-wounding. 
Nuclei counterstained with haematoxylin (blue). Inset i-iv represents a 64x 
121 
 
magnification of the dotted region in images on the top row. Arrows indicate α-
SMA postitive blood vessels. Area quantification was done on 4 high powered 
20x magnification field in each replicate. Decrease is not significant as 
determined by Student’s two-tailed t-test * p < 0.05. Error bars represent 
standard error. n = 2 wound replicates from the same rat. 
 
4.3.8 CPX+S1P reduces MMP-3 and MMP-13 expression 
 
Besides physical rearrangement by myofibroblasts, the compaction of collagen 
fibers is also regulated by matrix metalloproteinases (MMP). CPX+S1P 
treatment significantly (* p < 0.05) attenuated MMP-13 (collagenase-3) and also 
attenuated MMP-3 (stromelysin-1) expression by 40% in deep diabetic wounds 
(Figure 4.22; Methods §3.3.5). At higher magnification, changes in MMP-13 
expression pattern were striking (Figure 4.22, inset i-iv). In the control group, 
MMP-13 expression was diffusely distributed throughout the entire dermal 
matrix, while exposure to CPX+S1P resulted in a pericellular expression of 
MMP-13. Using a fluorescence resonance energy transfer (FRET) peptide as a 
MMP substrate (Methods §3.3.9), I found that CPX alone in vitro has the 
potential to dose-dependently inhibit APMA-activated MMP-3 activity while 
completely inhibiting APMA-activated MMP-13 at the lowest concentration 











Figure 4.22 Representative Immunohistochemical localization of MMP-3 and 
MMP-13 expression (brown) in granulation tissue of full-thickness deep diabetic 
wounds with or without 0.1mM CPX + 0.01mM S1P treatment 31 days post-
wounding. Nuclei counterstained with haematoxylin (blue). Inset i-iv shows the 
magnified images of the selected regions of interest i-iv in the top row. Graph 
reveals a 40% decrease in MMP-3 and MMP-13 expression in CPX+S1P 
treated granulation tissue. Area quantification was done at 20x magnification 
field. Significance * p < 0.05 determined by Student’s two-tailed t-test. Error bars 






Figure 4.23 In vitro MMP-3 and MMP-13 fluorometric assay reveals a dose 
dependent inhibition of APMA activated MMP-3 activity and a complete 
inhibition of MMP-13 with a CPX concentration of 1 µM.  “+” represents the 
positive control MMP-3 inhibitor V or MMP-13 inhibitor CL82198 hydrochloride.  
Significance * p < 0.05 determined by Student’s two-tailed t-test. Error bars 
represent standard error. n = replicate treatments. #: Reason for n < 3: a well 
was excluded due to the observable presence of air bubbles and/ or dust 


























I have demonstrated here the successful off-label use of anti-fungal drug 
ciclopirox clamine (CPX) in combination with sphingosine-1-phosphate (S1P) 
as an attractive proangiogenic drug combination for diabetic wound healing. 
Both CPX and S1P have been previously shown to be angiogenic on their own 
as monosubstances [241,279] and their combination was observed by our lab 
to further increase endothelial cell (EC) sprouting in vitro [21]. As an extension 
to this literature, I assessed if CPX+S1P is able to (i) hyperinduce the angiogenic 
master regulator HIF-1, (ii) potentiate angiogenesis in vivo and (iii) increase 
diabetic wound contraction.  
 
HIF-1 activation is a crucial angiogenic driver in upregulating the transcription 
of a variety of angiogenic stimulants [368].  HIF-1 is a heterodimer consisting of 
a constitutively-expressed HIF-1β subunit and an O2 – and growth factor-
regulated HIF-1α subunit [87] . Of these two subunits, the HIF-1α subunit is the 
limiting factor in the creation of a functional HIF-1 dimer [88]. HIF-1 activity is 
promoted by (i) an increase in HIF-1α stabilization [88] and/or (ii) an increase in 
HIF-1 transcriptional activity [243,244]. Increasing both upstream regulators 
concurrently results in a greater downstream transcription of angiogenic 
stimulants compared to increasing one regulator alone [283]. A previous study 
by Tal et al. (2008) demonstrated that a constitutively stable and a 
transcriptionally active HIF-1α transgene, when targeted into murine ECs, is 
able to effectively increase capillary density and blood flow in a hindlimb 
ischemia model [282, 283]. Nonetheless the long-term safety of human gene 
therapy remains a concern [226]. Here I demonstrated that the FDA-approved 
drugs - CPX and S1P potentially amplify both HIF-1 upstream regulators. 
126 
 
I observed in HUVECs that CPX+S1P increase the upstream regulator HIF-1α 
protein levels in a manner that exceeds its additive effect. It was previously 
shown that S1P increases HIF-1α translation through the activation of Gi protein 
pathway [280], while CPX inhibits HIF-1α degradation by Fe2+ chelation [159]. 
Here, Fe2+ is a cofactor for the prolyl and asparaginyl hydroxylases that 
continuously earmark the HIF-1α subunit for proteasomal degradation. As such, 
it can be speculated that CPX+S1P combination simultaneously leverages on 
both strategies i.e., increasing HIF-1α synthesis and inhibiting its degradation, 
to prolong HIF-1α’s otherwise short half-life.  
 
CPX+S1P also increases the protein expression of the HIF-1 transcription 
activator (phosphorylated-p42/44 MAPK) in a manner that exceeds its additive 
effect. However CPX alone inhibits the expression of phosphorylated-p42/44 
MAPK. A similar observation was also reported by Luo et al. (2011) in murine 
lymphatic EC cultures [281]. Interestingly, supplementation with S1P was able 
not only to override CPX’s suppressive effects and even potentiate it. To date, 
CPX’s inhibitory mechanism and S1P’s overriding mechanism remain to be 
elucidated.   
 
As HIF-1 upstream activity increases, there is a corresponding additive increase 
in its downstream angiogenic targets: c-MET, VEGF and eNOS [245]. Here c-
MET (hepatocyte growth factor receptor) was selected for assessment as it is 
previously reported to be a marker for the angiogenic phenotype of ECs; being 
up-regulated only in activated EC during in vitro sprouting and down-regulated 
upon differentiation into capillary-like structures [369]. c-MET also increases EC 
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proliferation and initiates a downstream cell invasion programme [370,371]. 
VEGF was assessed as it mediates vascular homeaostasis, EC survival and its 
absence attenuates EC motility [103,106].  eNOS was also assessed as its 
absence is known to seriously impair angiogenesis in a murine hindlimb 
ischemia model; which was not rescuable with the administration of a potent 
angiogenic recombinant VEGF protein [372], suggesting that eNOS is crucial in 
mediating a VEGF-induced angiogenesis [373].  
 
Having established that CPX+S1P hyperinduces the angiogenic master 
regulator HIF-1, I next assessed if it potentiates angiogenesis in vivo. Using a 
well-established subcutaneously implanted PVA sponge model, I demonstrated 
that combination of CPX+S1P indeed increases EC infiltration and functional 
vessel length in a manner that exceeds their additive effects. This corroborates 
with my group’s previous in vitro observation that CPX+S1P potentiates EC 
sprout length and infiltration in collagen gel with the formation of true lumina 
[21].  It is important to highlight here that the results should not be over 
interpreted given a small sample size from the same rat; and a larger sample 
size may highlight a possible dorso-ventral gradient of vascular density in rodent 
dorsum [374] in which a pair-wise analysis of sponges across rats may be 
required.  
 
As angiogenesis intimately supports skin wound contraction, I next assessed 
the efficacy of pro-angiogenic CPX+S1P drug treatment in promoting 
contraction in full-thickness diabetic skin wounds. To do so, I first identified the 
variables which may affect wound contraction. Kennedy et al. (1979) previously 
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reported that (i) animal age, (ii) species and (iii) position of wound on the body 
surface affects wound contraction; while  (i) sex of the animal, (ii) time of day of 
wounding, (iii) wound shape, or (iv) wound size (unless it is so large that it 
extends over different anatomical regions) do not [375]. Hence in my 
experiment, I standardized the wound size & located them at fixed distances 
with reference to the shoulder blade of each rat. Contralateral wounds were also 
treated with the same drug to avoid any systemic effects. Due to logistical 
arrangements, I was unable not commence surgery on all the rats at the same 
age; but all wounds were made on 18- to 20-week old rats.  
 
Treatment with CPX+S1P resulted in a striking increase in large (rather than 
small or medium) blood vessels in deep diabetic wounds. Previous in vitro 
findings by Nakatsu et al. [111] suggested that the lumina diameter of new 
sprouts is dependent on the activation of p42/44MAPK pathway in endothelial 
cells. I thus speculate that potentiation of p42/44 MAPK activity by CPX+S1P 
may be associated with the in vivo observation of large vessel formation. 
 
The observed increased angiogenesis paralleled a stronger accumulation of 
granulation tissue in deep diabetic wounds. This increase in collagen deposition 
was unexpected, as the prolyl hydroxylase inhibitor CPX is known to cross-
inhibit collagen prolyl hydroxylases, which would predict reduced collagen 
secretion and deposition [277]. In fact, granulation tissue increase had not been 
reported in high dose treatment diabetic murine wounds with 50 mM of CPX as 




In this study, the increase in collagen deposition was also associated with 
attenuated MMP levels. Diabetic tissue has been shown to overexpress MMPs, 
in particular MMP-13 and MMP-3 in diabetic ZDF rats [20]. MMP-13 degrades 
major dermal collagen subtypes I and III while MMP-3 degrades the dermal 
collagen subtypes III and IV. Using MMP antibodies that recognize total MMP 
level, CPX+S1P was clearly seen to attenuate both MMP-3 and MMP-13 
expression in diabetic wounds. Recent evidence supports a link between S1P 
and suppression of MMP-3, MMP-13 expression and activity in EC [284] and in 
human chondrocytes [285] by repressing NF-κB which binds to MMP promoters. 
In vitro, I saw strong inhibition of MMP-3 and MMP-13 activity by CPX alone, 
which may be partly due to its ability to chelate divalent cations [240] such as 
Zn2+ needed for MMP activity. Interestingly, the localisation of MMP-13 
expression resembled that of α-SMA. This may not come as surprise, as MMP-
13 was previously found to be expressed abundantly in fibroblastic cells in 
diabetic rodent wounds [20] and in human myofibroblasts [286].  
 
Cellular contractile forces generated by myofibroblasts are recognized as a 
contributing factor for granulation tissue compaction [287]. Nonetheless, 
CPX+S1P treatment did not appear to increase α-SMA expression of 
myofibroblasts. Instead, I observed a decrease that was spatially confined to 
the lower half of the granulation tissue. A direct zonal net effect of CPX+S1P on 
myofibroblast differentiation cannot be excluded at present, but this requires 
further detailed study. A more straightforward explanation for this observation is 
a recent discovery that mechanical tension exerted by splinting induces and 
maintains myofibroblast transdifferentiation [288]. In this study, the splints were 
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sutured through the dermis and panniculus carnosus but not through the 
superficial fascia and deep retinacula cutis adipose layer. Therefore, 
mechanical tension exerted by the splint would likely dominate the upper-half of 
the granulation tissue.  
 
As the proangiogenic CPX+S1P treatment promoted granulation tissue 
development, an increase in contraction in deep diabetic wounds followed. 
However, in superficial wounds, a granulation tissue driven contraction was not 
discernible despite an increase in angiogenesis (Appendix B). This is not 
surprising given that contraction in the control group remained extensive at 50 
%, even under splinting, masking any pharmacological effect. Such extensive 
contraction during wound healing is an inherent rodent-specific feature arising 
from skin laxity, which in humans may be more representative of wound healing 
in the trunk or perineum [16]. On the contrary, diabetic ulcers exhibit low wound 
contraction as they are commonly located in the lower- extremity where skin 
laxity is low [13] and granulation tissue development is slow [289]. Here I 
managed to emulate this pathology, by exploiting the presence of a dorsal fat 
pad in the Zucker fatty rat that lies cranial to the transverse plane, to increase 
the wound depth to ~3 mm. This allowed for the extrusion of the perilesional 
adipose layer into the deep wound void to retard excessive contraction due to 
skin laxity [264] whilst providing a large enough wound volume for the gradual 
development of granulation tissue. Compared to the superficial wounds of ~ 1 
mm depth, the deep wounds used in this dissertation is a closer representative 
of wounds in the human big toe, wherein soft tissue thickness ranges between 
4.5 mm to 10.1 mm [377]. Modulating wound depth is thus an elegant solution 
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for creating a rodent skin model which better emulates human wound healing 
tissue dynamics, and may pave the path for better assessment and 
understanding of promoters of diabetic wound healing.  
 
In conclusion, the clinically-used anti-fungal drug CPX and the bioactive lipid 
S1P represent an attractive drug combination to be repurposed for diabetic 
wound healing. The ability to amplify HIF-1 activity makes CPX+S1P 
advantageous in diabetic wounds as they are known to have attenuated HIF-1 
activity [153,154]. There might be more to this combination as CPX has also 
recently been shown to exhibit antibacterial activity [290], which may further add 
to its utility in treating diabetic wounds which are very susceptible to bacterial 
biofilm development. Additionally, as high density lipid-S1P plasma levels are 
known to be suppressed in severe diabetics [179], topical supplementation of 
S1P has the potential to be even more efficacious for wound treatment in this 
subset of patients. It is important to note that the results from the deep diabetic 
wounds were derived from a small sample size of two wounds from the same 
rat. Recently, Ansell et al. found that wounds derived from the same mouse 
showed high variability and could be considered as independent biological 
replicates [376]. Nonetheless, the results should not be over interpreted as a 
wound sample size beween one to four could hypothetically result in a 30% to 
50% difference in wound healing [376]. The reasons for the small sample size 
in this dissertation has been highlighted in Table 6; where many wounds were 
lost or excluded from analysis due to isoflurane overdosing, wound infections, 
diabetic complications and splints bitten off by the rats. The techniques I have 
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Conclusion,  















In this dissertation, I demonstrated the repurposing of two compounds for 
diabetic wound healing. I combined 
(i) Ciclopirox olamine (CPX), a divalent metal chelator FDA-approved as an anti-
fungal drug; and  
(ii) Sphingosine-1-phosphate (S1P), a lysophospholipid whose analogue is 
FDA-approved for multiple sclerosis treatment.  
 
The use of this combination was motivated by literature findings that: 
(1) Reversing impaired angiogenesis in diabetic wounds promotes granulation 
tissue accumulation and compaction, accelerating contraction (a wound 
closure mechanism); 
(2) Major inhibitors of angiogenesis can be reversed by divalent metal 
chelation and S1P supplementation;  
(3) CPX and S1P analogues are clinically used, supporting a drug repurposing 
approach to reduce translational hurdles; and 
(4) CPX and S1P previously demonstrated angiogenic synergy in vitro. 
 
As an extension of current literature, this dissertation provides the 
following new insights: 
(1) CPX+S1P potentiates a crucial driver of angiogenesis i.e., hypoxia-
inducible factor-1 activity in endothelial cells (EC) in vitro,  
(2) CPX+S1P potentiates EC infiltration and functional vessel length in a 
subcutaneous sponge implantation rodent model; 
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(3) CPX+S1P not only increased angiogenesis but also decreased matrix 
metalloproteinase levels in deep diabetic rodent wounds, resulting in a 
granulation-tissue driven wound contraction that increases wound closure.  
 
These findings are significant because:  
(1) Despite the widely perceived view that a broad band prolyl hydroxylase 
inhibitor potentially cross-inhibits collagen secretion, I found a surprising 
increase in collagen deposition in the presence of a low dose of CPX (0.1 
mM) as opposed to earlier studies using topical doses up to 50 mM [130]. 
 
(2) Current rodent models have not revealed wound sites that allow for wound 
depth variation. Leveraging on a recent Zucker diabetic fatty rat wound 
healing model [20], I identified specific wound sites that allow varying of the 
full thickness skin wound depth from 1 mm (superficial) to 3 mm (deep). This 
modified model has important clinical translational implications in assessing 
the efficacy of pharmacological treatments in wound healing. I found that 
the same pharmacological treatment, though not as effective in promoting 
granulation tissue in superficial wounds, was effective in deep wounds.  
 
(3) Despite the widely perceived view that splinting retards excessive 
spontaneous wound contraction in rodents, I found that contraction 
remained significant at ~50% in splinted diabetic wounds. I present a simple 
method using wound depth increment (in the presence of splinting) to limit 
wound contraction to ~8%. This elegant solution overcomes spontaneous 
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contraction in rodents enabling me to assess granulation-driven wound 
contraction akin to human tissue.   
 
As the above conclusions are drawn from a small sample size (n = 2 to 8), 
the next section (§6.2) highlights the limitations in this small study and the 
further need for larger confirmatory work. 
 
6.2 Limitations and future work 
 
Small studies advantageously allow the Hypothesis to be addressed within a 
short span of time while avoiding spending too much finances on finding an 
association when there really is no effect. Nonetheless, a major drawback of 
small studies is that they can under- or over-estimate the magnitude of an 
association particularly when experimental limitations are not highlighted.  This 
section thus discusses experimental limitations and suggests future work that 
may address the limitations. 
 
6.2.1 Preparing a stable S1P solution  
 
The first experimental limitation concerns the preparation of a stable 
Sphingosine-1-phosphate (S1P) stock solution. As discussed in §3.1.3, this 
method involves dispersing S1P by sonication in an aqueous buffer solution 
containing serum albumin [291]. In an aqueous solution, S1P has a low solubility. 
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Hence serum albumin serves as S1P’s carrier by binding reversibly to it 
[292,293]. Immediately after sonication, the S1P stock solution is clear and 
devoid of precipitates. However, when kept for more than 12 hours on a shaker 
at 4oC, precipitates begin to form. The further use of this unstable S1P solution 
could not induce the hypoxia-inducible factor-1 (HIF-1) activity in HUVECs 
described in §4.1. This efficacy was only seen when a freshly sonicated S1P 
stock solution was used. For future clinical applications, it may be pertinent to 
assess techniques that prolong S1P’s solubility; for example by the addition of 
biocompatible surfactants [294].  
 
6.2.2 Imaging functional vessels  
   
The second set of limitations concerns the procedure of imaging functional 
vessels in Polyvinyl alcohol (PVA) sponge explants. As discussed in §3.2, FITC-
isolectin was first perfused through the rodent tail vein. The PVA sponges were 
thereafter harvested, bisected, cryosectioned and stained with anti-FITC and 
RECA-1 antibodies to detect FITC-isolectin and endothelial cells respectively.  
 
The limitations observed in this procedure were: 
 
(1) An assumption was made that 1 ml of FITC-isolectin at 0.5 µg/µl was 
sufficiently high enough to label most or all of the EC along the perfused 
vessels in rats. (Note: The volume and concentration were adapted from 
Kang et al.’s (2011) successful perfusion of FITC-isolectin in mice to detect 
functional vessels in subcutaneously implanted matrigels [295]. To 
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compensate for larger-sized rats, I have increased the FITC-isolectin 
volume by 10 times [from 0.1 ml to 1 ml] as the rat was approximately 10 
times heavier than a mouse.) 
 
(2) Up to 20% loss in FITC-isolectin perfusion volume can occur while trying 
to align needle in the tail vein. Such volume loss may not be considered 
negligible and needs to be correspondingly compensated in future work. 
 
(3) It can be challenging to obtain intact 1 µm cryosections at similar depths 
across all sponges as these thin sections tended to tear under steel 
microtome blades. Future work could consider the use of glass knives 
tailored for ultramicrotomy.  (Note: Ultrathin sections were needed to allow 
for a cleaner wash off of non-specific antibodies retained by hydrophilic 
PVA material. For thick sections, high magnification was used to image 
vessels away from the porous PVA walls.)   
 
Future work can consider the use of X-ray microcomputed tomography (micro-
CT) to image functional vasculature. This technique avoids the histological 
challenges faced. Here rats are first perfused with a contrast agent and micro-
CT is then used to visualize the vasculature at the site of interest in intact rats. 
A three-dimensional reconstruction image of functional vessels is generated. 
Using a variety of algorithms for advanced quantitative analysis, the vessel 
volume, diameter and degree of anisotropy can be calculated from the 
tomographic data [296]. Moreover, micro-CT also allows for measurements of 
vessel permeability and blood perfusion [297].  This may be particularly relevant 
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for diabetics who are often plagued with microvascular stasis owing to their low 
red blood cell (RBC) deformability [298]. As CPX+S1P was observed to increase 
the large blood vessel density in diabetic wounds (§4.3.6), it may be speculated 
that CPX+S1P increases blood perfusion. Micro-CT may provide a more 
conclusive determination. Alternatively, the following non-invasive techniques 
can be used to measure wound perfusion: 
 
(i) Laser Doppler imaging, which provides a two-dimensional map of 
microvascular flow over the entire wound surface; and 
(ii) transcutaneous oximetry, which reflects the amount of oxygen diffused 
from the capillaries through the epidermis at perilesional sites. 
 
Both techniques confer the major advantage of real time visualization of wound 
perfusion without contrast agents, allowing researchers to monitor perfusion 
development in the same animal over time. 
 
6.2.3 Managing diabetic complications in rats 
 
The third set of limitations concerns the full thickness skin wound model in obese 
female Zucker Diabetic Fatty (ZDF) rats. Here I observed that:   
 
(1) ZDF rats are hypersensitive to isoflurane. 
(2) ZDF diabetic rats develop urinary tract infections. 
(3) ZDF diabetic rats develop abdomen pressure sores. 
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(4) ZDF rats tended to actively bite off parts of the bandage to access the 
wound. 
(5) Sutures attached to the splint surfaced at various time points during the 
third   week post-surgery. 
 
To address these complications, I found the following techniques useful: 
 
(1)To prevent isoflurane overdosing during a 45 minute dorsal wound 
excision surgery, oxygen levels was doubled to 2 atm and isoflurane 
levels varied between 1 % and 3 %. (Note: Overdosing was observe to 
occur after a 45 minutes continuous exposure to 1 atm oxygen and 2% 
isoflurane). 
(2)To reduce urinary tract infection, 5 ml of saline was injected daily 
subcutaneously. 
(3)To reduce pressure sores, rats were encouraged to move freely by taping 
wound dressings only to its back and not entirely across the dorsum and 
upper abdomen. 
(4)To prevent the bandage from being completely bitten off, the bandage 
was double folded to increase its thickness and replaced daily. 
(5)To reattach the splint to the skin after sutures have surfaced, superglue 
was applied daily to the splint. Resuturing was avoided as it may induce 
additional trauma to the wound. Nonetheless, future work would need to 
standardize the time point to remove all sutures across the rats as the 
glue and sutures may exert different tensions on the perileisional skin 
affecting wound closure. 
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6.2.4 Measuring wound contraction  
 
The fourth set of limitations concerns the method of measuring wound 
contraction histologically (§4.3.4): 
 
(1) Histological contraction measurements may not be representative of 
overall wound contraction. In rats, mid-dorsal wound contraction is not 
uniform. There is a tendency for the lateral edges of the wound to move 
closer together than the anterior and posterior edges [15]. Thus 
contraction measurements in this study may be more representative of 
central wound contraction wherein histological measurements were 
taken. This may not be directly comparable to macroscopic 
measurements done in other studies. 
  
(2)  Wounds with a high fat content tend to tear easily when sectioning. 
Hence it can be challenging to derive intact sections from similar depth 
intervals across all rats.  
 
Future work to assess overall wound contraction can be done through 
macroscopic measurements of tattooed perilesional skin. In this approach India 
ink is use to tattoo grids around the dermal edges of the wound defect to locate 
the original defect perimeter without ambiguity [15]. Thereafter, planimetry or 
computerized morphometric image analysis is used to measure the defect area 
over time [15]. However, this approach may be challenging for splinted wound 
models as tattooed marks are concealed by glued splints.  
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6.2.5 Limited efficacy in re-epithelialization  
 
The fifth limitation concerns the lack of efficacy by CPX+S1P in promoting re-
epithelialization (§4.3.4). As discussed in §2.1, the wound closure mechanism 
involves both contraction and re-epithelialization. Both mechanisms are 
impaired in chronic wounds [13,28]. To futher accelerate diabetic wound 
closure, future work may consider combining CPX+S1P with re-epithelialization 
activating treatments. An example of such treatments involves downregulating 
overexpressed desmosomes and hemidesmosomes in the epidermis [303,304].  
 
6.2.6 Non-clinical representation of wound environment 
 
The sixth limitation concerns the use of a sterile and non-ischemic diabetic 
wound model. This may not be representative of the clinical challenges such as 
the persistent infections in diabetic wounds plagued with ischemia [299]. Here 
traditional route of systemic antibiotic delivery is ineffective with a poor wound 
perfusion. Such prolong infections can significantly impede wound healing rates 
by 40% [300]. To better represent these clinical challenges, future work can 
modify the diabetic ZDF wound model to exhibit: 
 
(1) ischemia, by surgical incisions to generate a bipedicle dorsal skin flap 
[301], and 
(2) infection, by introducing well-known virulence bacteria such as S. aureus, 




Evaluating the efficacy of CPX+S1P to promote diabetic wound healing under 
these additional casual factors allows for a more conclusive assessment of its 
translational robustness. 
 
6.3 Concluding Remark 
 
This dissertation provides a proof of concept that the CPX+S1P is an attractive 































Biological dressings: Cell-free and Cell-containing matrices  
Immediate wound coverage has been a major tool in diabetic wound 
management. Since the early 1500s, skin grafts have been used to restore 
wound defects [378]. However, concerns over the availability of sufficient 
healthy skin, the health risks associated with the procedure and donor-site 
morbidity have been a cause for concern. These disadvantages have led to the 
development of 3-dimensional tissue-engineered biodegradable skin scaffolds. 
These scaffolds are laid over the wound site and are gradually infiltrated by cells 
and incorporated into the wound bed. They can be classified into two categories: 
(i) cell-free matrices or (ii) cell-containing matrices.  
 
Cell-free matrices 
Examples of cell-free matrices used clinically on diabetic foot ulcers are:  
1) Promogran (Johnson & Johnson, New Brunswick, NJ), a combination of 
55% collagen and 45% oxidized regenerated cellulose matrix [379]; 
2) Fibracol (Medline Industries Inc., Mundelein, Illinois), a combination of 
90% collagen and 10% calcium alginate [380]; 
3) Formulated Collagen gel (Cardium Therapeutics Inc., San Diego, CA), a 
2.6% bovine collagen in a specialized buffer [381]; 
4) Oasis® (Healthpoint Ltd, Fort Worth, TX), collagen matrix derived from 
submucosa of porcine small intestine [382]; 
5) Graftjacket (Kinetic Concepts Inc, San Antonio, TX), a decellularized 
human dermal matrix [383];  
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6) Integra® (Integra LifeSciences, Plainsboro, NJ), bovine tendon collagen 
and glycosaminoglycan matrix [384]. 
 
These collagen containing matrices serve to absorb and trap the wound 
exudates which contain high levels of MMP; thereby reducing matrix 
degradation [385]. The presence of polysaccharides in some of these matrices 
is said to bind iron and zinc which are catalysts for ROS generation and MMP 
activity respectively, resulting in a reduction of MMP (MMP-2, MMP-9) and ROS 
levels [386]. Polysaccharides also bind and stabilize growth factors, allowing 
them to be re-delivered in their active form when the biodegradable matrices 
are re-absorb [387]. Nonetheless, the efficacy of these cell-free matrices in 
decreasing the mean time of healing was only as effective as that of standard 
treatment with a moisten gauze [205]. It remains unknown if these matrices 
address the impaired HIF-1 activity in diabetic wounds to promote the release 
of downstream angiogenic stimulants. It is believed that a combinatory 
treatment of growth factor supplementation and cell-free matrice is a more 
efficacious approach in wound healing than an individual treatment with cell-free 
matrice [225].  
 
Cell-containing matrices 
Cell-containing matrices propose to provide an additional advantage to cell-free 
matrices by including growth factor releasing allogenic or autologous cells such 
as keratinocytes or fibroblasts. Allogenic cells can be cultured more rapidly than 
adult cells. This permits immediate graft availability with the possibility for bulk 
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manufacturing [230]. Examples of cell-containing matrices used clinically on 
diabetic foot are: 
 
1) Dermagraft (Advanced Biohealing Westport, CT, USA), human neonatal 
foreskin fibroblast embedded in a three-dimensional polyglactin scaffold 
[388]; 
2) Apligraf® (Organogenesis Inc., Canton, MA), a bi-layer skin product with 
the dermal layer consisting of neonatal foreskin fibroblast embedded in 
a bovine collagen matrix covered by an epidermal layer with human 
keratinocytes [389]; 
3) OrCel® (Ortec International Inc., New York, NY, USA), a bi-layer skin 
product with the dermal layer consisiting of a porous collagen sponge 
containing cocultured allogeneic keratinocytes and fibroblasts 
harvested from human neonatal foreskin [390, 391];  
4) EpiDex® (Euroderm GmbH, Germany, Leipzig), autologous fully 
differentiated, stratified keratinocytes derived from the patient’s outer 
root hair sheath [392]. 
 
Although these cell-containing matrices are capable of secreting and releasing 
multiple angiogenic growth factors such as PDGF-BB into the wound bed [393], 
the success and survival of this bioengineered skin depends on a well-
vascularised wound bed. Its clinically effectiveness was reportedly seen only in 
non-ischemic and non-infected, chronic plantar diabetic foot ulcer [205, 394]. 
Moreover the time taken for matrices such as Integra to be re-vascularised is 
clinically long (~10 days to 15 days) [393]. As the viability of these cells 
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decrease, the efficacy of the matrice also decreases [395]. The introduction of 
allogenic cells come with several additional disadvantages such as a short shelf-
life of 5-days, an increase risk of disease transmittance and a poor-cost to 
benefit ratio [396]. Fibroblast-seeded products such as DermaMatrix cost ~30-
60 USD per square centimeter and are much more costly than cell-free matrices 
[396]. The addition of the keratinocyte layer such as in Apligraf doubles the cost 
[396]. Moreover, with a short life span of allogenic cells, these matrices are 
temporary and will be replaced one to two months later with a split thickness 
skin autograft [393]. 
 
Modalities: NPWT, USH, HBO  
Besides biological dressings, three modalities: 1) negative pressure wound 
therapy (NPWT), 2) ultrasound healing therapy (USH) and 3) hyperbaric oxygen 
therapy (HBO), have emerged with a proposed efficacy that increases HIF-1 
activity and reduces MMP levels in diabetic wounds. 
 
Negative pressure wound therapy (NPWT) 
NPWT is approved by FDA since 1995 (Vacuum Assisted Closure, Kinetic 
Concepts Inc., San Antonio, TX) [397]. This technology involves creating a 
tightly sealed dressing around the wound and thereafter a suction pump is 
applied to create a continuous or intermitted negative pressure across the 
wound. This process drains the bacteria laden and high MMP wound exudates 
[398]. With negative pressures of ~125mmHg, tissue deformation occurs at the 
wound edges occluding capillary vessels [399, 400]. A ~0.5 cm ischemic zone 
is induced at the wound edges while perfusion ~2.5cm away from the wound 
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edge is increased [399, 400]. This transient ischemia at the wound edge is 
believe to trigger a release of HIF-1 downstream pro-angiogenic such as VEGF, 
bFGF, TGF-β, PDGF-B, which results in an increase in microvessel density, 
lumen size, and granulation tissue formation [399, 401 - 403]. Although NPWT 
is widely regarded as safe and effective, its efficacy is only seen in wound beds 
that are well-vascularised [404, 405], with limited benefit in ischemic wounds 
[399, 406, 407]. Moreover NPWT may further induce necrosis at wound edges 
of ischemic wounds [405]. As NPWT has to be given for at least 22 hours per 
day for an optimal outcome, the patient’s quality of life may be comprised [399, 
408]. Patients may also experience an initial pain with negative pressure suction 
[399, 408]. Depending on the pressure magnitude and cyclical application, its 
angiogenic efficacy remains debatable with several studies observing no 
benefits in increasing HIF-1 activity and pro-angiogenic growth factor levels 
(reviewed in Glass et al., 2014) [401]. It remains unknown if NPWT aids in 
decreasing ROS and AGE levels, and if it increases S1P levels in the diabetic 
wound. Clinical studies comparing NPWT to standard care (advance moist 
wound therapy, saline gauze) showed no conclusive improvements in the mean 
time of diabetic ulcer healing [401]. 
 
Ultrasound Healing therapy (USH) 
USH (MIST Therapy, Celleration, Inc., Eden Prairie, MN) is approved by FDA 
since 2005 to deliver noncontact low-energy ultrasound to the wound bed 
through a continuous saline mist [409]. Ultrasound is defined as a mechanical 
vibration transmitted at a frequency above the upper limit of human hearing (>20 
kilohertz). USH induces mechanical deformation of the cell membrane 
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stimulating mechanical transduction signals in fibroblasts to increase secretion 
pro-angiogenic growth factors such as TGF-β1 and VEGF production [410, 
411]. USH also increases p42/44 MAPK signalling [411], which may contribute 
to an increased vessel size observed in USH treated diabetic murine wounds 
[111, 412]. Nonetheless, it remains unknown if USH decreases ROS, AGE and 
MMP levels and if it increases S1P levels in the diabetic wound. A recent review 
by Game et al. (2012) reported few randomised controlled trials to support the 
use of USH in promoting diabetic wound healing [413]. 
 
Hyperbaric oxygen therapy (HBO) 
HBO therapy is an expensive therapy which requires the patient to breathe an 
intermittent administration of 100% oxygen under elevated atmospheric 
pressures, for a few hours over 30-40 sessions [414]. HBO clinical trials for 
diabetic foot ulcers healing was first reported in 1987 by Baroni and colleagues. 
During treatment, the arterial oxygen tension often exceeds 2000 mmHg and 
levels of 200 to 400 mmHg occur in tissues [414]. Oxygen inhaled under 
elevated pressure dissolves in plasma, in the absence of haemoglobin. Its 
diffusion from functional capillaries depends on oxygen partial pressure instead 
of haemoglobin levels. As such, oxygen diffusion into the wound increase with 
an increase in atmospheric pressure.  HBO elevates wound oxygen tension 
levels, promoting fibroblast replication and collagen deposition [415]. 
Nonetheless, its efficacy in increasing angiogenesis in diabetic wounds remains 
unclear. Conflicting data surrounds HBO’s ability to increase HIF-1 activity and 
its downstream angiogenic stimulants [416, 417]. Studies supporting an 
increase in HIF-1 activity propose that HBO first increases ROS level, which in 
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turn increases antioxidants production such as thioredoxin and thioredoxin 
reductase, which is a non-hypoxia activator of HIF-1 [416, 418]. A recent clinical 





















Figure B1. Angiogenesis in granulation tissue of superficial diabetic wounds 
with or without 0.1mM CPX + 0.01mM S1P treatment 14 days post-wounding. 
(A) Representative Immunohistochemical localization of RECA-1 positive 
endothelial cells (EC) (brown). Nuclei counterstained with haematoxylin (blue).  
Graph of RECA-1 positive area reveals a significant increase in EC infiltration 
with CPX+S1P. Area quantification was done on 12 20x magnification field in 
each replicate (B) Graph of vessel density of small vessels (cross-sectional area 
<200 µm2), medium vessels (cross-sectional area between 200 µm2 and 1000 
µm2) and large vessels (cross-sectional area >1000 µm2) induced with or 
without CPX+S1P treatment. Functional vessels i.e., RECA-1 positive lumina 
containing red blood cells, are represented by solid areas. Vessel density 
quantified from 24 random sites in each treatment condition. Significance * p < 
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Figure B2. Representative Masson’s trichrome blue stained granulation tissue 
of superficial diabetic wounds 14 days post-treatment with or without 0.1 mM 
CPX + 0.01 mM S1P. Collagen area (blue stain) thresholded using ImageJ. 
Graph reveals no significant increases in granulation tissue thickness 
Quantification done at 20x magnification field. Significance * p < 0.05, is derived 
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